,CAS,URL,Highest Development Event Status and Year,Highest Development Event Source ID,Highest Development Event Source URL,Earliest Approved Event Status and Year,Earliest Approved Event Source ID,Earliest Approved Event Source URL,conditions,phases
0,51022-69-6,https://drugs.ncats.io/drug/423W026MA9,US Approved Rx 2003,ANDA076065,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=076065,US Previously Marketed 1979,CYCLOCORT by ASTELLAS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018116,Corticosteroid-responsive dermatoses,Approved
1,90-84-6,https://drugs.ncats.io/drug/Q94YYU22B8,US Approved Rx 2011,ANDA091680,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=091680,US Previously Marketed 1959,TEPANIL by 3M,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011673,Unknown; Exogenous obesity; Unknown,Approved
2,300-62-9,https://drugs.ncats.io/drug/CK833KGX7E,US Approved Rx 2003,ANDA040480,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=040480,US Previously Marketed 1931,Benzedrine Inhaler,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2377281/,Attention deficit hyperactivity disorder,Approved
3,20537-88-6,https://drugs.ncats.io/drug/ILA426L95O,US Approved Rx 1995,NDA020221,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020221,US Approved Rx 1995,NDA020221,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020221,Ovarian cancer; Head and neck cancer,Approved; Approved
4,37517-28-5,https://drugs.ncats.io/drug/84319SGC3C,US Approved Rx 1993,ANDA064045,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=064045,US Previously Marketed 1976,AMIKIN by APOTHECON,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050495,Cystic fibrosis; Sepsis; Urinary tract infections; Meningitis; Pneumonia,Phase III; Approved; Approved; Approved; Phase III
5,2609-46-3,https://drugs.ncats.io/drug/7DZO8EB0Z3,US Approved Rx 2009,ANDA079133,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=079133,US Previously Marketed 1981,MODURETIC 5-50 by MERCK,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018201,Hypertension; Heart failure,Approved; Approved
6,2097132-02-8,https://drugs.ncats.io/drug/71RR81V666,Clinical ,INN:iodine (¹³¹I) apamistamab [INN],https://ginas.ncats.nih.gov/ginas/app/substance/71RR81V666,,,,,
7,90-45-9,https://drugs.ncats.io/drug/78OY3Z0P7Z,US Previously Marketed 1934,Aminacrine,https://books.google.com/books?id=jglFsz5EJR8C&lpg=PA381&ots=DG2kaw3Z_a&dq=AMINACRINE%20first%20marketed&pg=PA381#v=onepage&q=AMINACRINE%20first%20marketed&f=false,US Previously Marketed 1934,Aminacrine,https://books.google.com/books?id=jglFsz5EJR8C&lpg=PA381&ots=DG2kaw3Z_a&dq=AMINACRINE%20first%20marketed&pg=PA381#v=onepage&q=AMINACRINE%20first%20marketed&f=false,Adult T-cell leukemia/lymphoma; Vaginal trichomoniasis; Mycoses,Basic research; Phase I; Approved
8,60-32-2,https://drugs.ncats.io/drug/U6F3787206,US Approved Rx 2021,ANDA213825,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213825,US Previously Marketed 1964,AMICAR by EPIC PHARMA LLC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=015229,Bleeding,Approved
9,125-84-8,https://drugs.ncats.io/drug/0O54ZQ14I9,US Previously Marketed 1960,Elipten by Ciba,DeHaen 1940-1975 NMEs,US Previously Marketed 1960,Elipten by Ciba,DeHaen 1940-1975 NMEs,Cushing’s disease,Approved
10,106-60-5,https://drugs.ncats.io/drug/88755TAZ87,US Approved Rx 2017,NDA208630,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208630,Possibly Marketed Outside US 1995,ANDA077614,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0bfea06d-7abe-407a-80a4-d15d373569f7,Condylomata acuminata; Malignant glioma; Actinic keratosis,Approved; Approved; Approved
11,317-34-0,https://drugs.ncats.io/drug/27Y3KJK423,US Approved Rx 1983,ANDA087943,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=087943,US Previously Marketed 1921,Theophylline U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Airway obstruction,Approved
12,504-29-0,https://drugs.ncats.io/drug/WSX981HEWU,,,,,,,,
13,65-49-6,https://drugs.ncats.io/drug/5B2658E0N2,US Approved Rx 1994,ANDA074346,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=074346,US Previously Marketed 1948,Pamisyl by Parke-Davis,DeHaen 1940-1975 NMEs,Tuberculosis; Crohn's disease; Ulcerative colitis,Approved; Phase II; Phase II
14,1951-25-3,https://drugs.ncats.io/drug/N3RQ532IUT,US Approved Rx 2008,ANDA077234,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=077234,US Previously Marketed 1985,CORDARONE by WYETH PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018972,Ventricular tachycardia; Recurring ventricular fibrillation,Approved; Approved
15,50-48-6,https://drugs.ncats.io/drug/1806D8D52K,US Approved Rx 1987,ANDA089400,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=089400,US Previously Marketed 1961,ELAVIL by ASTRAZENECA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012703,Depressive disorder,Approved
16,68302-57-8,https://drugs.ncats.io/drug/BRL1C2459K,US Previously Marketed 2004,AMLEXANOX by ULURU,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021727,US Previously Marketed 1996,APHTHASOL by ULURU,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020511,Aphthous ulcers,Approved
17,88150-42-9,https://drugs.ncats.io/drug/1J444QC288,US Approved Rx 2015,ANDA202829,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202829,Possibly Marketed Outside US 1987,NDA019787,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d233a645-805b-45be-ae20-534367bc15ff,Coronary artery disease; Hypertension; Chagas disease,Approved; Approved; Preclinical
18,7664-41-7,https://drugs.ncats.io/drug/5138Q19F1X,US Approved Rx 1984,ANDA088366,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=088366,US Previously Marketed 1921,Ammonium Chloride U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Metabolic alkalosis,Approved
19,14798-03-9,https://drugs.ncats.io/drug/54S68520I4,US Approved Rx 1984,ANDA088366,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=088366,US Previously Marketed 1921,Ammonium Chloride U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Metabolic alkalosis,Approved
20,57-43-2,https://drugs.ncats.io/drug/GWH6IJ239E,US Previously Marketed 1923,amobarbital,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2424120/,US Previously Marketed 1923,amobarbital,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2424120/,Anxiety; Insomnia,Approved; Approved
21,14028-44-5,https://drugs.ncats.io/drug/R63VQ857OT,US Approved Rx 1992,ANDA072691,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=072691,US Previously Marketed 1980,ASENDIN by LEDERLE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018021,Neurotic or reactive depressive disorders; Psychotic depressions,Approved; Approved
22,26787-78-0,https://drugs.ncats.io/drug/9EM05410Q9,US Approved Rx 2005,ANDA065191,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=065191,US Previously Marketed 1973,AMOXIL by GLAXOSMITHKLINE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050459,"Infections of the ear, nose, and throat; Skin and skin structure infections; Gonorrhea, acute uncomplicated; Helicobacter pylori infection and duodenal ulcer disease; Infections of the genitourinary tract",Approved; Approved; Approved; Approved; Approved
23,300-62-9,https://drugs.ncats.io/drug/CK833KGX7E,US Approved Rx 2003,ANDA040480,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=040480,US Previously Marketed 1931,Benzedrine Inhaler,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2377281/,Attention deficit hyperactivity disorder,Approved
24,1397-89-3,https://drugs.ncats.io/drug/7XU7A7DROE,US Approved Rx 2021,ANDA212514,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212514,US Previously Marketed 1958,Fungizone by Squibb,DeHaen 1940-1975 NMEs,Cryptococcosis; Zygomycosis; Histoplasmosis; Visceral leishmaniasis; Mucormycosis; Coccidioidomycosis; Blastomycosis; Candida infections; Aspergillus infections; Sporotrichosis; Naeglerias; Mycoses,Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Preclinical; Preclinical
25,69-53-4,https://drugs.ncats.io/drug/7C782967RD,US Approved Rx 1993,ANDA062797,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=062797,US Previously Marketed 1963,POLYCILLIN by BRISTOL,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050310,Bacterial Infections,Approved
26,161814-49-9,https://drugs.ncats.io/drug/5S0W860XNR,US Approved Rx 2016,ANDA204060,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204060,US Previously Marketed 1999,AGENERASE by GLAXOSMITHKLINE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021039,HIV-1 infection,Approved
27,60719-84-8,https://drugs.ncats.io/drug/JUT23379TN,US Approved Rx 2000,ANDA075513,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=075513,US Previously Marketed 1984,INOCOR by SANOFI AVENTIS US,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018700,Congestive heart failure,Approved
28,463-04-7,https://drugs.ncats.io/drug/H2HUX79FYK,US Previously Marketed 1880,Amyl Nitrite U.S.P.,https://books.google.com/books?id=WO5NAAAAMAAJ&newbks=1&newbks_redir=0&dq=united%20states%20pharmacopeia%201880&pg=PA14#v=onepage&q=amyl%20nitrite&f=false,US Previously Marketed 1880,Amyl Nitrite U.S.P.,https://books.google.com/books?id=WO5NAAAAMAAJ&newbks=1&newbks_redir=0&dq=united%20states%20pharmacopeia%201880&pg=PA14#v=onepage&q=amyl%20nitrite&f=false,,
29,60-29-7,https://drugs.ncats.io/drug/0F5N573A2Y,US Previously Marketed 1921,Ether U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,US Previously Marketed 1846,ether,https://catalog.hathitrust.org/Record/100782317,,
30,68475-42-3,https://drugs.ncats.io/drug/K9X45X0051,US Approved Rx 2017,ANDA209151,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209151,US Approved Rx 1997,NDA020333,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=20333,,
31,143090-92-0,https://drugs.ncats.io/drug/9013DUQ28K,US Approved Rx 2001,BLA103950,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103950,US Approved Rx 2001,BLA103950,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103950,,
32,120511-73-1,https://drugs.ncats.io/drug/2Z07MYW1AZ,US Approved Rx 2010,ANDA090568,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=090568,US Approved Rx 1995,NDA020541,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020541,Breast cancer,Approved
33,1262449-58-0,https://drugs.ncats.io/drug/BI009E452R,Possibly Marketed Outside US ,WHO-ATC:V03AB38,https://ginas.ncats.nih.gov/ginas/app/substance/BI009E452R,Possibly Marketed Outside US 2018,BLA125586,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae7f0c50-ff2d-49e5-8e10-4efa861556e6,,
34,482-27-9,https://drugs.ncats.io/drug/20GCF755G6,,,,,,,Skin cancer,Basic research
35,138402-11-6,https://drugs.ncats.io/drug/J0E2756Z7N,US Approved Rx 2012,ANDA077369,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=077369,US Approved Rx 1997,NDA020758,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020758,Hypertension; Diabetic nephropathy,Approved; Approved
36,166663-25-8,https://drugs.ncats.io/drug/9HLM53094I,US Approved Rx 2006,NDA021632,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021632,US Approved Rx 2006,NDA021632,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021632,Esophageal candidiasis; Candidemia,Approved; Approved
37,117-37-3,https://drugs.ncats.io/drug/S747T1ERAJ,US Previously Marketed 1957,MIRADON by SCHERING,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=010909,US Previously Marketed 1957,MIRADON by SCHERING,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=010909,Pulmonary embolism; Coronary occlusion; Atrial fibrillation with embolization; Venous thrombosis,Approved; Approved; Approved; Approved
38,471-34-1,https://drugs.ncats.io/drug/H0G9379FGK,US Approved OTC ,21 CFR 331.11(i)(2) antacid:calcium-containing calcium (mono or dibasic salt),https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec331-11.xml,US Previously Marketed 1921,Precipitated Calcium Phosphate N.F.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Unknown; Hypocalcemia; Chronic obstructive pulmonary disease; Cystic fibrosis; Unknown; Hypocalcemia,Not Provided; Phase I; Phase I; Approved
39,91-75-8,https://drugs.ncats.io/drug/DHA8014SS1,US Previously Marketed 1990,VASOCON-A by NOVARTIS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018746,US Previously Marketed 1948,Antistine Phosphate by Ciba,DeHaen 1940-1975 NMEs,Allergic conjunctivitis,Approved
40,977007-26-3,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
41,69-72-7,https://drugs.ncats.io/drug/O414PZ4LPZ,US Approved OTC ,21 CFR 358.110(b) wart remover:collodoin-like vehicle salicylic acid,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec358-110.xml,US Previously Marketed 1860,sodium salicylate,https://catalog.hathitrust.org/Record/100782317,Psoriasis; Ichthyosis vulgaris; Keratosis palmaris; Bruises; Arthritis; Strains and sprains; Simple backache,Approved; Approved; Approved; Approved; Approved; Approved; Approved
42,69-72-7,https://drugs.ncats.io/drug/O414PZ4LPZ,US Approved OTC ,21 CFR 358.110(b) wart remover:collodoin-like vehicle salicylic acid,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec358-110.xml,US Previously Marketed 1860,sodium salicylate,https://catalog.hathitrust.org/Record/100782317,Psoriasis; Ichthyosis vulgaris; Keratosis palmaris; Bruises; Arthritis; Strains and sprains; Simple backache,Approved; Approved; Approved; Approved; Approved; Approved; Approved
43,112-05-0,https://drugs.ncats.io/drug/97SEH7577T,US Previously Marketed 1960,Pellar by Crookes-Barnes (Cooper),DeHaen 1940-1975 NMEs,US Previously Marketed 1960,Pellar by Crookes-Barnes (Cooper),DeHaen 1940-1975 NMEs,Seizure; Unknown,Preclinical
44,58-73-1,https://drugs.ncats.io/drug/8GTS82S83M,US Approved OTC ,21 CFR 336.10(c) antiemetic diphenhydramine hydrochloride,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec336-10.xml,US Previously Marketed 1946,BENADRYL by MCNEIL CONS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=005845,Occasional sleeplessness; Seasonal allergic rhinitis,Approved; Approved
45,7440-36-0,https://drugs.ncats.io/drug/9IT35J3UV3,US Previously Marketed 1921,Wine of Antimony N.F.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,US Previously Marketed 1921,Wine of Antimony N.F.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,,
46,9000-94-6,https://drugs.ncats.io/drug/T0LTO7L82X,Possibly Marketed Outside US ,Thrombate III by Grifols Therapeutics Llc [Canada],https://www.drugbank.ca/drugs/DB11598,Possibly Marketed Outside US 1991,BLA103196,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b2a9f856-3ef7-8da4-920c-f738e4f1f7d7,,
47,956104-40-8,https://drugs.ncats.io/drug/4T36H88UA7,US Approved Rx 2018,NDA210951,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210951,US Approved Rx 2018,NDA210951,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210951,Prostate cancer,Approved
48,503612-47-3,https://drugs.ncats.io/drug/3Z9Y7UWC1J,US Approved Rx 2019,ANDA210171,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210171,US Approved Rx 2012,NDA202155,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202155,Embolism and thrombosis; Stroke,Approved; Approved
49,58-00-4,https://drugs.ncats.io/drug/N21FAR7B4S,US Approved Rx 2022,ANDA212025,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212025,US Previously Marketed 1880,apomorphia,https://catalog.hathitrust.org/Record/100782317,Parkinson's disease,Approved
50,69-72-7,https://drugs.ncats.io/drug/O414PZ4LPZ,US Approved OTC ,21 CFR 358.110(b) wart remover:collodoin-like vehicle salicylic acid,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec358-110.xml,US Previously Marketed 1860,sodium salicylate,https://catalog.hathitrust.org/Record/100782317,Psoriasis; Ichthyosis vulgaris; Keratosis palmaris; Bruises; Arthritis; Strains and sprains; Simple backache,Approved; Approved; Approved; Approved; Approved; Approved; Approved
51,66711-21-5,https://drugs.ncats.io/drug/843CEN85DI,US Approved Rx 1987,NDA019779,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019779,US Approved Rx 1987,NDA019779,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019779,Ocular hypertension,Approved
52,608141-41-9,https://drugs.ncats.io/drug/UP7QBP99PN,US Approved Rx 2024,ANDA211734,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211734,US Approved Rx 2014,NDA205437,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205437,"Psoriasis; Arthritis, psoriatic",Approved; Approved
53,170729-80-3,https://drugs.ncats.io/drug/1NF15YR6UY,US Approved Rx 2008,NDA022023,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022023,US Approved Rx 2003,NDA021549,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021549,Postoperative nausea and vomiting; Chemotherapy induced nausea and vomiting; Chemotherapy induced nausea and vomiting; Postoperative nausea and vomiting,Approved; Approved; Approved; Approved
54,9087-70-1,https://drugs.ncats.io/drug/ba8b95ec,,,,,,,,
55,9036-66-2,https://drugs.ncats.io/drug/SL4SX1O487,Possibly Marketed Outside US 2013,21 CFR 352,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a9dfa6b8-4b1a-4233-91f0-ad7423b2e04f,Possibly Marketed Outside US 2009,21 CFR 352,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=44318cdb-aa87-0b09-e054-00144ff8d46c,,
56,91745-67-4,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
57,9041-08-1,https://drugs.ncats.io/drug/19GW9E1WHN,Clinical ,INN:sevuparin sodium [INN],https://ginas.ncats.nih.gov/ginas/app/substance/19GW9E1WHN,,,,,
58,67346-49-0,https://drugs.ncats.io/drug/F91H02EBWT,US Approved Rx 2021,ANDA200293,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=200293,US Approved Rx 2006,NDA021912,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021912,Chronic obstructive pulmonary disease,Approved
59,108778-82-1,https://drugs.ncats.io/drug/S866O45PIG,US Approved Rx 1991,BLA020032,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020032,US Approved Rx 1991,BLA020032,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020032,,
60,141388-76-3,https://drugs.ncats.io/drug/BFE2NBZ7NX,US Approved Rx 2009,NDA022308,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022308,US Approved Rx 2009,NDA022308,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022308,Bacterial conjunctivitis,Approved
61,7235-40-7,https://drugs.ncats.io/drug/01YAE03M7J,US Previously Marketed 1975,SOLATENE by ROCHE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017589,Possibly Marketed Outside US 1964,UDDER BALM by H. W. Naylor Company Inc.,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2907f343-4457-bf36-2e0b-aa074e63a4bd,"Macular degeneration; Neuroblastoma; Head and neck cancer; Retinitis pigmentosa; Psoriasis; Chronic pancreatitis; Cardiovascular diseases; Maternal mortality, fetal loss, or infant mortality; Erythropoietic protoporphyria",Phase III; Basic research; Phase III; Phase III; Phase III; Phase III; Phase II; Phase III; Approved
62,5638-76-6,https://drugs.ncats.io/drug/X32KK4201D,US Previously Marketed 1966,Serc by Unimed More,DeHaen 1940-1975 NMEs,US Previously Marketed 1966,Serc by Unimed More,DeHaen 1940-1975 NMEs,Meniere's disease,Approved
63,107-43-7,https://drugs.ncats.io/drug/3SCV180C9W,US Approved Rx 2021,ANDA214864,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214864,US Previously Marketed 1880,Betain,https://books.google.com/books?id=hg5KAAAAMAAJ&newbks=1&newbks_redir=0&dq=betaine%20cooley&pg=PA316#v=onepage&q=betaine&f=false,Homocystinuria,Approved
64,378-44-9,https://drugs.ncats.io/drug/9842X06Q6M,US Approved Rx 2020,NDA213422,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213422,US Previously Marketed 1961,CELESTONE by SCHERING,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012657,Congenital adrenal hyperplasia; Lymphomas; Asthma; Allergic rhinitis; Ulcerative colitis; Acute exacerbations of multiple sclerosis,Approved; Approved; Approved; Approved; Approved; Approved
65,63659-18-7,https://drugs.ncats.io/drug/O0ZR1R6RZ2,US Approved Rx 2009,ANDA078694,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=078694,US Approved Rx 1985,NDA019270,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019270,Open-angle glaucoma; Ocular hypertension; Hypertension,Approved; Approved; Approved
66,674-38-4,https://drugs.ncats.io/drug/004F72P8F4,US Approved Rx 1978,ANDA086263,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=086263,US Previously Marketed 1948,URECHOLINE by ODYSSEY PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=006536,Urinary retention,Approved
67,330942-05-7,https://drugs.ncats.io/drug/74RWP7W0J9,US Previously Marketed 2017,BEVYXXA by PORTOLA PHARMS INC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208383,US Previously Marketed 2017,BEVYXXA by PORTOLA PHARMS INC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208383,Venous thromboembolism; venous thromboembolism,Phase III; Approved
68,216974-75-3,https://drugs.ncats.io/drug/2S9ZZM9Q9V,US Approved Rx 2019,BLA761099,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761099,US Approved Rx 2004,BLA125085,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125085,,
69,153559-49-0,https://drugs.ncats.io/drug/A61RXM4375,US Approved Rx 2018,ANDA209861,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209861,US Approved Rx 1999,NDA021055,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021055,Cutaneous T-cell lymphoma,Approved
70,1246264-45-8,https://drugs.ncats.io/drug/4H5YMK1H2E,US Approved Rx 2016,BLA761046,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761046,US Approved Rx 2016,BLA761046,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761046,,
71,90357-06-5,https://drugs.ncats.io/drug/A0Z3NAU9DP,US Approved Rx 2015,ANDA091011,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=091011,US Approved Rx 1995,NDA020498,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020498,Stage D2 metastatic carcinoma of the prostate,Approved
72,1611493-60-7,https://drugs.ncats.io/drug/8GB79LOJ07,US Approved Rx 2018,NDA210251,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210251,US Approved Rx 2018,NDA210251,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210251,HIV-1 infection,Approved
73,155206-00-1,https://drugs.ncats.io/drug/QXS94885MZ,US Approved Rx 2015,ANDA203991,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203991,US Previously Marketed 2001,LUMIGAN by ABBVIE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021275,Ocular hypertension; Open-angle glaucoma,Approved; Approved
74,606143-89-9,https://drugs.ncats.io/drug/181R97MR71,US Approved Rx 2018,NDA210498,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210498,US Approved Rx 2018,NDA210498,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210498,BRAF V600E-mutant metastatic colorectal cancer; Metastatic or unresectable cutaneous melanoma,Phase III; Approved
75,153-18-4,https://drugs.ncats.io/drug/5G06TVY3R7,US Previously Marketed 1921,rutin,https://catalog.hathitrust.org/Record/100163146,US Previously Marketed 1921,rutin,https://catalog.hathitrust.org/Record/100163146,Osteoarthritis; Open-angle glaucoma; Postmastectomy lymphoedema of the arm,Approved; Phase II; Approved
76,58-85-5,https://drugs.ncats.io/drug/6SO6U10H04,US Approved Rx 2000,NDA021163,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021163,US Previously Marketed 1947,BEROCCA PN by ROCHE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=006071,Vitamin deficiency; Biotin deficiency,Approved; Approved
77,514-65-8,https://drugs.ncats.io/drug/0FRP6G56LD,US Previously Marketed 1959,AKINETON by ABBVIE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012003,US Previously Marketed 1959,AKINETON by ABBVIE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012003,Idiopathic Parkinson's disease; Postencephalitic parkinsonism; Arteriosclerotic parkinsonism,Approved; Approved; Approved
78,603-50-9,https://drugs.ncats.io/drug/10X0709Y6I,US Previously Marketed 1958,Dulcolax by Geigy,DeHaen 1940-1975 NMEs,US Previously Marketed 1958,Dulcolax by Geigy,DeHaen 1940-1975 NMEs,Constipation,Withdrawn
79,7440-69-9,https://drugs.ncats.io/drug/U015TT5I8H,US Previously Marketed 1921,Bismuth Magma U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,US Previously Marketed 1921,Bismuth Magma U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,,
80,66722-44-9,https://drugs.ncats.io/drug/Y41JS2NL6U,US Approved Rx 2024,ANDA217617,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217617,US Previously Marketed 1992,ZEBETA by TEVA WOMENS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019982,Hypertension,Approved
81,30392-40-6,https://drugs.ncats.io/drug/9KY0QXD6LI,US Previously Marketed 1992,TORNALATE by SANOFI AVENTIS US,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019548,US Previously Marketed 1984,TORNALATE by SANOFI AVENTIS US,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018770,Asthma; Chronic obstructive pulmonary disease,Approved; Approved
82,128270-60-0,https://drugs.ncats.io/drug/TN9BEX005G,US Approved Rx 2019,NDA211215,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211215,US Approved Rx 2000,NDA020873,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020873,unstable angina,Approved
83,11056-06-7,https://drugs.ncats.io/drug/40S1VHN69B,US Approved Rx 2001,ANDA065042,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=065042,US Previously Marketed 1973,BLENOXANE by BRISTOL MYERS SQUIBB,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050443,"Squamous cell carcinoma, cervix; Malignant pleural effusion; Squamous cell carcinoma, vulva; Non-Hodgkin's lymphoma; Squamous cell carcinoma, penis; Embryonal cell, choriocarcinoma; Head and neck squamous cell carcinoma; Hodgkin's lymphoma; Teratocarcinoma; Hodgkin's lymphoma; Non-Hodgkin's lymphoma; Malignant pleural effusion; Testicular cancer; Squamous cell carcinoma",Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved
84,853426-35-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
85,394730-60-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
86,10043-35-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
87,179324-69-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
88,147536-97-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
89,380843-75-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
90,173740-48-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
91,914088-09-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
92,59-41-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
93,913611-97-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
94,1197953-54-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
95,633-03-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
96,59803-98-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
97,138890-62-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
98,357336-20-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
99,108333-82-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
100,35531-88-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
101,839712-12-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
102,78-44-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
103,9000-11-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
104,154-93-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
105,8015-86-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
106,305-84-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
107,7235-40-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
108,11103-57-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
109,51781-06-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
110,72956-09-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
111,8024-48-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
112,9000-71-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
113,162808-62-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
114,606138-08-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
115,53994-73-3,https://drugs.ncats.io/drug/3Z6FS3IK0K,US Approved Rx 2002,ANDA065058,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=065058,US Previously Marketed 1979,CEFACLOR by CEPH INTL,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=062205,Pharyngitis; Lower respiratory tract infections; Otitis media; Skin and skin structure infections; Urinary tract infections; Tonsillitis,Approved; Approved; Approved; Approved; Approved; Approved
116,50370-12-2,https://drugs.ncats.io/drug/Q525PA8JJB,US Approved Rx 2007,ANDA065352,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=065352,US Previously Marketed 1978,Duracef by Mead Johnson,OB NME Appendix 1950-1985,Bacterial infections,Approved
117,15686-71-2,https://drugs.ncats.io/drug/5SFF1W6677,US Approved Rx 2005,ANDA065253,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=065253,US Previously Marketed 1971,KEFLEX by PRAGMA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050405,Bacterial Infections,Approved
118,34444-01-4,https://drugs.ncats.io/drug/5CKP8C2LLI,US Previously Marketed 1978,MANDOL by LILLY,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050504,US Previously Marketed 1978,MANDOL by LILLY,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050504,,
119,21593-23-7,https://drugs.ncats.io/drug/89B59H32VN,,,,,,,Bacterial infections,Approved
120,25953-19-9,https://drugs.ncats.io/drug/IHS69L0Y4T,US Approved Rx 1988,ANDA062831,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=062831,US Previously Marketed 1973,ANCEF by GLAXOSMITHKLINE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050461,Genital Infections; Urinary tract infections; Respiratory tract infections; Sepsis,Approved; Approved; Approved; Approved
121,91832-40-5,https://drugs.ncats.io/drug/CI0FAO63WC,US Approved Rx 2007,ANDA065473,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=065473,US Previously Marketed 1997,OMNICEF by ABBVIE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050749,Acute maxillary sinusitis; Uncomplicated skin and skin-structure infections; Tonsillitis; Pharyngitis; Acute exacerbations of chronic bronchitis; Community-acquired pneumonia,Approved; Approved; Approved; Approved; Approved; Approved
122,117467-28-4,https://drugs.ncats.io/drug/78THA212DH,US Previously Marketed 2001,SPECTRACEF by VANSEN PHARMA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021222,US Previously Marketed 2001,SPECTRACEF by VANSEN PHARMA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021222,Pharyngitis; Community-acquired pneumonia; Tonsillitis; Uncomplicated skin and skin-structure infections; Acute bacterial exacerbation of chronic bronchitis,Approved; Approved; Approved; Approved; Approved
123,88040-23-7,https://drugs.ncats.io/drug/807PW4VQE3,US Approved Rx 2020,ANDA212721,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212721,US Previously Marketed 1996,MAXIPIME by HOSPIRA INC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050679,Pneumonia; Complicated intra-abdominal infections; Urinary tract infections; Febrile neutropenia; Uncomplicated skin and skin-structure infections,Approved; Approved; Approved; Approved; Approved
124,79350-37-1,https://drugs.ncats.io/drug/XZ7BG04GJX,US Approved Rx 2013,NDA202091,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202091,Possibly Marketed Outside US 1986,ANDA065355,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d0fd45bd-7d52-4fa6-a5f7-f46d5651ffa2,Otitis media; Pharyngitis; Gonorrhea; Chronic bronchitis; Urinary tract infections,Approved; Approved; Approved; Approved; Approved
125,56796-20-4,https://drugs.ncats.io/drug/3J962UJT8H,US Previously Marketed 1989,ZEFAZONE by PHARMACIA AND UPJOHN,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050637,US Previously Marketed 1989,ZEFAZONE by PHARMACIA AND UPJOHN,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050637,Intra-abdominal infections; Respiratory tract infections; Urinary tract infections; Gynecologic infections; Skin and soft tissue infections,Approved; Approved; Approved; Approved; Approved
126,61270-58-4,https://drugs.ncats.io/drug/6532B86WFG,US Previously Marketed 1984,MONOCID by GLAXOSMITHKLINE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050579,US Previously Marketed 1984,MONOCID by GLAXOSMITHKLINE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050579,Bacterial infections,Approved
127,62893-19-0,https://drugs.ncats.io/drug/7U75I1278D,US Previously Marketed 1982,CEFOBID by PFIZER,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050551,US Previously Marketed 1982,CEFOBID by PFIZER,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050551,Sepsis; Urinary tract infections; Peritonitis and other intra-abdominal infections; Skin and skin structure infections; Pelvic inflammatory disease; Respiratory tract infections,Approved; Approved; Approved; Approved; Approved; Approved
128,63527-52-6,https://drugs.ncats.io/drug/N2GI8B1GK7,US Previously Marketed 2010,CEFOTAXIME SODIUM by CEPHAZONE PHARMA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=065348,US Previously Marketed 1981,CLAFORAN by STERIMAX,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050547,Lower respiratory tract infections; Urinary tract infections; Uncomplicated gonorrhea; Intra-abdominal infections; Central nervous system infections; Bone and joint infections; Skin and skin structure infections; Gynecologic infections; Sepsis,Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved
129,69712-56-7,https://drugs.ncats.io/drug/48SPP0PA9Q,US Approved Rx 2007,ANDA065374,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=065374,US Previously Marketed 1985,CEFOTAN by PAI HOLDINGS PHARM,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050588,Urinary tract infections; Intra-abdominal infections; Skin and skin structure infections; Bone and joint infections; Lower respiratory tract infections; Gynecologic infections,Approved; Approved; Approved; Approved; Approved; Approved
130,35607-66-0,https://drugs.ncats.io/drug/6OEV9DX57Y,US Approved Rx 2009,ANDA065414,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=065414,US Previously Marketed 1978,MEFOXIN by MYLAN INSTITUTIONAL,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050517,Lower respiratory tract infections; Peritonitis; Urinary tract infections,Approved; Approved; Approved
131,87239-81-4,https://drugs.ncats.io/drug/2TB00A1Z7N,US Approved Rx 2007,ANDA065388,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=065388,US Previously Marketed 1992,BANAN by SANKYO,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050687,"Acute bacterial exacerbation of chronic bronchitis; Acute, uncomplicated urethral and cervical gonorrhea; Acute maxillary sinusitis; Uncomplicated skin and skin-structure infections; Cystitis; Acute, uncomplicated ano-rectal infections in women; Community-acquired pneumonia; Tonsillitis; Pharyngitis; Acute otitis media",Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved
132,92676-86-3,https://drugs.ncats.io/drug/S1SDI2FJIY,Possibly Marketed Outside US ,Apo-cefprozil by Apotex Corporation [Canada],https://www.drugbank.ca/drugs/DB01150,,,,Unknown,
133,38821-53-3,https://drugs.ncats.io/drug/9YA6SX5S4D,US Previously Marketed 1977,VELOSEF by APOTHECON,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=061976,US Previously Marketed 1974,ANSPOR by GLAXOSMITHKLINE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=061859,Respiratory tract infections; Skin and skin structure infections; Urinary tract infections; Otitis media,Approved; Approved; Approved; Approved
134,229016-73-3,https://drugs.ncats.io/drug/7P6FQA5D21,US Approved Rx 2010,NDA200327,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=200327,US Approved Rx 2010,NDA200327,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=200327,Acute bacterial skin and skin structure infection; Community-acquired bacterial pneumonia,Approved; Approved
135,72558-82-8,https://drugs.ncats.io/drug/DZR1ENT301,US Approved Rx 1986,ANDA062662,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=062662,US Previously Marketed 1985,FORTAZ by PAI HOLDINGS PHARM,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050578,Urinary tract infections; Skin and skin structure infections; Lower respiratory tract infections; Cystic fibrosis,Approved; Approved; Approved; Phase IV
136,97519-39-6,https://drugs.ncats.io/drug/IW71N46B4Y,US Previously Marketed 1995,Cedax,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=50685,US Previously Marketed 1995,Cedax,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=50685,Acute bacterial otitis media; Acute bacterial exacerbation of chronic bronchitis; Pharyngitis; Tonsillitis,Approved; Approved; Approved; Approved
137,68401-81-0,https://drugs.ncats.io/drug/C43C467DPE,US Previously Marketed 1983,CEFIZOX by ASTELLAS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050560,US Previously Marketed 1983,CEFIZOX by ASTELLAS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050560,Meningitis caused by Haemophilus influenzae; Urinary tract infections; Lower respiratory tract infections; Gonorrhea; Pelvic inflammatory disease,Approved; Approved; Approved; Approved; Approved
138,689293-68-3,https://drugs.ncats.io/drug/37A4IES95Q,US Approved Rx 2014,NDA206829,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206829,US Approved Rx 2014,NDA206829,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206829,Pyelonephritis; Intra-abdominal infections,Approved; Approved
139,7773-52-6,https://drugs.ncats.io/drug/CUB7JI0JV3,US Previously Marketed 1941,Ceepryn by Merrell,DeHaen 1940-1975 NMEs,US Previously Marketed 1941,Ceepryn by Merrell,DeHaen 1940-1975 NMEs,Gingivitis; Dental plaque,Approved; Approved
140,107233-08-9,https://drugs.ncats.io/drug/K9V0CDQ56E,US Approved Rx 2023,ANDA215056,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215056,US Approved Rx 2000,NDA020989,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020989,Sjogren's syndrome,Approved
141,16291-96-6,https://drugs.ncats.io/drug/bb1e7d07,,,,,,,,
142,12141-46-7,https://drugs.ncats.io/drug/T1FAD4SS2M,US Previously Marketed 1921,sodium aluminosilicate,https://catalog.hathitrust.org/Record/100163146,US Previously Marketed 1921,sodium aluminosilicate,https://catalog.hathitrust.org/Record/100163146,Hypertension,Approved
143,15686-51-8,https://drugs.ncats.io/drug/95QN29S1ID,,,,,,,Allergic rhinitis; Urticaria,Approved; Approved
144,167221-71-8,https://drugs.ncats.io/drug/19O2GP3B7Q,US Approved Rx 2008,NDA022156,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022156,US Approved Rx 2008,NDA022156,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022156,Hypertension,Approved
145,7020-55-5,https://drugs.ncats.io/drug/BO76JF850N,US Approved Rx 2022,ANDA215453,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215453,US Previously Marketed 1956,QUARZAN by ROCHE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=010355,Acute enterocolitis; Irritable bowel syndrome; Intestinal spasm; Peptic ulcer,Approved; Approved; Approved; Approved
146,18323-44-9,https://drugs.ncats.io/drug/3U02EL437C,US Approved Rx 2012,ANDA090979,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=090979,US Approved Rx 1970,NDA050162,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050162,Serious skin infections; Infections of the female pelvis; Serious respiratory tract infections; Intra-abdominal infections; Infections of the genital tract; Serious soft tissue infections; Sepsis; Acne vulgaris; Lower respiratory tract infections; Gynecological infections; Skin and skin structure infections; Sepsis; Bone and joint infections; Intra-abdominal infections,Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved
147,130-26-7,https://drugs.ncats.io/drug/7BHQ856EJ5,US Approved OTC ,21 CFR 333.210(a) antifungal clioquinol,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec333-210.xml,US Previously Marketed 1961,NYSTAFORM by BAYER PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050235,Pruritus Ani; Eczema; Dermatitis,Approved; Approved; Approved
148,22316-47-8,https://drugs.ncats.io/drug/2MRO291B4U,US Approved Rx 2018,ANDA211449,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211449,US Approved Rx 2011,NDA202067,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202067,Lennox-Gastaut syndrome,Approved
149,25122-41-2,https://drugs.ncats.io/drug/ADN79D536H,US Approved Rx 2017,ANDA210199,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210199,US Previously Marketed 1985,TEMOVATE by FOUGERA PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019323,Inflammatory and pruritic dermatoses,Approved
150,4828-27-7,https://drugs.ncats.io/drug/N8ZUB7XE0H,US Approved Rx 1977,NDA017765,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017765,US Approved Rx 1977,NDA017765,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017765,Dermatoses,Approved
151,123318-82-1,https://drugs.ncats.io/drug/762RDY0Y2H,US Approved Rx 2017,ANDA205375,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205375,US Approved Rx 2004,NDA021673,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021673,Relapsed or refractory acute lymphoblastic leukemia,Approved
152,2030-63-9,https://drugs.ncats.io/drug/D959AE5USF,US Previously Marketed 1986,LAMPRENE by NOVARTIS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019500,US Previously Marketed 1986,LAMPRENE by NOVARTIS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019500,Lepromatous leprosy,Approved
153,791-35-5,https://drugs.ncats.io/drug/42C50P12AP,US Approved OTC ,21 CFR 341.14(a)(1) cough/cold:antitussive chlophedianol hydrochloride,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec341-14.xml,US Previously Marketed 1960,Ulo by Riker,OB NME Appendix 1950-1985,Cough,Approved
154,637-07-0,https://drugs.ncats.io/drug/HPN91K7FU3,US Previously Marketed 1967,ATROMID-S by WYETH AYERST,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016099,US Previously Marketed 1967,ATROMID-S by WYETH AYERST,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016099,Multiple myeloma; Hyperlipoproteinemia,Basic research; Approved
155,15690-55-8,https://drugs.ncats.io/drug/3JU1DU3652,US Approved Rx 1999,ANDA075528,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=075528,US Previously Marketed 1967,CLOMID by SANOFI AVENTIS US,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016131,Ovulatory dysfunction,Approved
156,303-49-1,https://drugs.ncats.io/drug/NUV44L116D,US Approved Rx 2020,ANDA213221,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213221,US Approved Rx 1989,NDA019906,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019906,Obsessive-compulsive disorder,Approved
157,1622-61-3,https://drugs.ncats.io/drug/5PE9FDE8GB,US Approved Rx 2019,ANDA211033,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211033,Possibly Marketed Outside US 1975,NDA017533,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bda569c3-106c-41c1-913c-6f6e8e60bfd4,Seizure disorders; Panic disorder,Approved; Approved
158,4205-90-7,https://drugs.ncats.io/drug/MN3L5RMN02,US Approved Rx 1986,ANDA070974,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=070974,US Previously Marketed 1974,COMBIPRES by BOEHRINGER INGELHEIM,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017503,Attention deficit hyperactivity disorder; Opioid withdrawal; Hypertension,Approved; Phase IV; Approved
159,113665-84-2,https://drugs.ncats.io/drug/A74586SNO7,US Approved Rx 2014,ANDA204165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204165,US Approved Rx 1997,NDA020839,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020839,Atherosclerosis; Acute coronary syndrome; Myocardial infarction; Peripheral arterial disease,Approved; Approved; Approved; Approved
160,23887-31-2,https://drugs.ncats.io/drug/D51WO0G0L4,US Approved Rx 2022,ANDA213730,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213730,US Approved Rx 1972,NDA017105,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017105,Anxiety; Partial seizures,Approved; Approved
161,23593-75-1,https://drugs.ncats.io/drug/G07GZ97H65,US Approved OTC ,21 CFR 333.210(g) antifungal clotrimazole,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec333-210.xml,US Previously Marketed 1975,LOTRIMIN by SCHERING PLOUGH,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017619,Tinea corporis; Vaginal yeast infections; Tinea cruris; Tinea pedis,Approved; Approved; Approved; Approved
162,61-72-3,https://drugs.ncats.io/drug/O6X5QGC2VB,US Previously Marketed 1989,CLOXACILLIN SODIUM by TEVA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=062978,US Previously Marketed 1965,TEGOPEN by APOTHECON,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050192,Bacterial otitis; Septicaemia; Septic arthritis; Urinary tract infections; Infective endocarditis; Respiratory tract infections; Bacterial osteomyelitis; Meningitis; Skin and soft tissue infections,Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved
163,130-16-5,https://drugs.ncats.io/drug/BPF36H1G6S,US Previously Marketed ,21 CFR 310.545(a)(1) acne chlorhydroxyquinoline (cloxyquin),https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec310-545.xml,,,,Tuberculosis; Migraine; Cryptosporidium parvum infection,Basic research; Basic research; Basic research
164,5786-21-0,https://drugs.ncats.io/drug/J60AR2IKIC,US Approved Rx 1989,NDA019758,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019758,US Approved Rx 1989,NDA019758,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019758,Treatment-resistant schizophrenia,Approved
165,8007-45-2,https://drugs.ncats.io/drug/R533ESO2EC,US Approved OTC ,21 CFR 358.710(b)(1) dandruff:seborrheic dermatitis coal tar,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec358-710.xml,US Previously Marketed 1921,Coal Tar N.F.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,,
166,7440-48-4,https://drugs.ncats.io/drug/3G0H8C9362,US Previously Marketed ,21 CFR 310.502(a) certain drugs cobalt,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec310-502.xml,,,,,
167,13870-90-1,https://drugs.ncats.io/drug/F0R1QK73KB,Possibly Marketed Outside US ,"BumP DHA by Centurion Labs, LLC",https://www.drugbank.ca/drugs/DB11191,Possibly Marketed Outside US 2011,EnLyte by Jaymac Pharma,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e83b2dd3-a9a0-40bc-ade4-6cd4db433b06,,
168,1004316-88-4,https://drugs.ncats.io/drug/LW2E03M5PG,US Approved Rx 2015,NDA205395,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205395,US Approved Rx 2012,NDA203100,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203100,HIV-1 infection,Approved
169,934660-93-2,https://drugs.ncats.io/drug/ER29L26N1X,US Approved Rx 2015,NDA206192,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206192,US Approved Rx 2015,NDA206192,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206192,Unresectable or metastatic melanoma with a BRAF V600E or V600K mutation,Approved
170,50-36-2,https://drugs.ncats.io/drug/I5Y540LHVR,US Approved Rx 2017,NDA209963,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209963,US Previously Marketed 1860,Cocaine,https://catalog.hathitrust.org/Record/100782317,Cocaine-related disorders; Procedures and surgeries on or through accessible mucous membranes of the nasal cavities,Phase IV; Approved
171,154-87-0,https://drugs.ncats.io/drug/XMK8K8EVIU,Possibly Marketed Outside US ,"EnBrace HR by Jaymac Pharmaceuticals, Llc",https://www.drugbank.ca/drugs/DB01987,Possibly Marketed Outside US 2011,EnBrace HR by Jaymac Pharma,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f14fa40-97ab-4ec5-b66b-793d6d1abac9,Vitamin deficiency; Vitamin deficiency,Phase I; Approved
172,124-87-8,https://drugs.ncats.io/drug/ZLT174DL7U,US Previously Marketed ,21 CFR 310.545(a)(25)(i) pediculicide picrotoxin,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec310-545.xml,,,,,
173,76-57-3,https://drugs.ncats.io/drug/UX6OWY2V7J,US Approved OTC ,21 CFR 341.14(a)(2)(ii) cough/cold:antitussive codeine phosphate,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec341-14.xml,US Previously Marketed 1921,Codeine Sulphate U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Pain,Approved
174,8001-69-2,https://drugs.ncats.io/drug/BBL281NWFG,US Approved OTC ,21 CFR 346.14(b)(2) anorectal:protectant cod liver oil (in combination only),https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec346-14.xml,US Previously Marketed 1921,Cod Liver Oil U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,,
175,64-86-8,https://drugs.ncats.io/drug/SML2Y3J35T,US Approved Rx 2016,ANDA204711,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204711,US Previously Marketed 1921,Colchicine U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Gout; Familial mediterranean fever,Approved; Approved
176,67-97-0,https://drugs.ncats.io/drug/1C6V77QF41,US Approved Rx 2000,NDA021163,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021163,US Previously Marketed 1921,vitamin D,https://catalog.hathitrust.org/Record/100163146,Vitamin D deficiency,Approved
177,182815-43-6,https://drugs.ncats.io/drug/1XU104G55N,US Approved Rx 2023,ANDA212886,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212886,US Previously Marketed 2000,WELCHOL by COSETTE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021141,Type 2 diabetes mellitus; Familial hypercholesterolemia; Primary hyperlipidemia,Approved; Approved; Approved
178,50925-79-6,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
179,11041-12-6,https://drugs.ncats.io/drug/4B33BGI082,US Approved Rx 2020,ANDA209599,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209599,US Previously Marketed 1964,Cuemid by Merck Sharp & Dohme,DeHaen 1940-1975 NMEs,,
180,16110-51-3,https://drugs.ncats.io/drug/Y0TK0FS77W,US Approved Rx 2000,ANDA075271,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=075271,US Previously Marketed 1973,INTAL by SANOFI AVENTIS US,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016990,Asthma; Allergic rhinitis; Allergic conjunctivitis; Mastocytosis; Allergic rhinitis; Vernal keratoconjunctivitis; Bronchial asthma,Approved; Approved; Approved; Approved; Approved; Approved; Approved
181,124236-29-9,https://drugs.ncats.io/drug/2EEH27851Y,US Approved Rx 1955,NDA009112,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=009112,US Previously Marketed 1949,EURAX by JOURNEY,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=006927,Unknown; Pruritus; Scabies,Approved; Approved
182,76-14-2,https://drugs.ncats.io/drug/6B5VVT93AR,Clinical ,INN:cryofluorane,https://tripod.nih.gov/npc/#Download,,,,,
183,472-70-8,https://drugs.ncats.io/drug/6ZIB13GI33,Clinical 2014,NCT02065024: Phase 1 Interventional Completed Hypercholesterolemia,https://clinicaltrials.gov/ct2/show/NCT02065024,,,,,
184,548-62-9,https://drugs.ncats.io/drug/J4Z741D6O5,US Previously Marketed 1977,GENAPAX by KEY PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=085017,US Previously Marketed 1921,gentian violet,https://catalog.hathitrust.org/Record/100163146,Fungal infection; Bacterial infections,Approved; Approved
185,458-37-7,https://drugs.ncats.io/drug/IT942ZTH98,Possibly Marketed Outside US ,Kaydia Patch by Strong Current Enterprises Limited,https://www.drugbank.ca/drugs/DB11672,Possibly Marketed Outside US 2009,21 CFR 348,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0fdc9bac-a0c4-4a8f-a36d-1a113b5bfa6d,Asthma; Schizophrenia; Mucositis; Colon cancer; Prostate cancer,Not Provided; Preclinical; Phase II; Phase I; Phase III
186,458-37-7,https://drugs.ncats.io/drug/IT942ZTH98,Possibly Marketed Outside US ,Kaydia Patch by Strong Current Enterprises Limited,https://www.drugbank.ca/drugs/DB11672,Possibly Marketed Outside US 2009,21 CFR 348,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0fdc9bac-a0c4-4a8f-a36d-1a113b5bfa6d,Asthma; Schizophrenia; Mucositis; Colon cancer; Prostate cancer,Not Provided; Preclinical; Phase II; Phase I; Phase III
187,68-19-9,https://drugs.ncats.io/drug/P6YC3EG204,US Approved Rx 2020,ANDA213874,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213874,US Previously Marketed 1947,BEROCCA PN by ROCHE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=006071,Folic acid deficiency; Malignancy of pancreas or bowel; Fish tapeworm infestation; Addisonian (pernicious) anemia,Approved; Approved; Approved; Approved
188,456-59-7,https://drugs.ncats.io/drug/4139O1OAY2,US Previously Marketed 1958,Cyclospasmol by Ives-Cameron (Ives),OB NME Appendix 1950-1985,US Previously Marketed 1958,Cyclospasmol by Ives-Cameron (Ives),OB NME Appendix 1950-1985,Intermittent claudication; Alzheimer’s disease,Approved; Approved
189,82-92-8,https://drugs.ncats.io/drug/QRW9FCR9P2,US Approved OTC ,21 CFR 336.10(a) antiemetic cyclizine hydrochloride,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec336-10.xml,US Previously Marketed 1953,Marezine by Burroughs Wellcome,OB NME Appendix 1950-1985,Motion sickness; Vomiting associated with radiotherapy; Postoperative nausea and vomiting,Approved; Approved; Approved
190,93413-62-8,https://drugs.ncats.io/drug/NG99554ANW,US Approved Rx 2018,ANDA210014,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210014,US Approved Rx 2008,NDA021992,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021992,Major depressive disorder,Approved
191,1392826-25-3,https://drugs.ncats.io/drug/P341G6W9NB,US Approved Rx 2017,NDA209885,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209885,US Approved Rx 2017,NDA209885,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209885,Huntington's disease; Tardive dyskinesia,Approved; Approved
192,50-02-2,https://drugs.ncats.io/drug/7S5I7G3JQL,US Approved Rx 2020,ANDA210966,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210966,US Previously Marketed 1958,DECADRON by MERCK,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011664,Cyclitis; Iritis; Herpes zoster keratitis; Allergic conjunctivitis; Acne rosacea; Superficial punctate keratitis; Corneal injury; Bacterial conjunctivitis; Multiple myeloma,Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved
193,51-64-9,https://drugs.ncats.io/drug/TZ47U051FI,US Approved Rx 1976,NDA017078,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017078,US Previously Marketed 1937,Dexedrine by Smith Kline French,https://web.archive.org/web/20091219120223/http://www.medic8.com/medicines/Dexedrine.html,Attention deficit hyperactivity disorder; Moderate to severe binge eating disorder; Attention deficit hyperactivity disorder,Approved; Approved; Approved
194,132-21-8,https://drugs.ncats.io/drug/75T64B71RP,US Approved OTC ,21 CFR 341.12(d) cough/cold:antihistamine dexbromopheniramine maleate,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec341-12.xml,US Previously Marketed 1959,Disomer by White (Schering),DeHaen 1940-1975 NMEs,Common cold; Allergic rhinitis,Approved; Approved
195,25523-97-1,https://drugs.ncats.io/drug/3Q9Q0B929N,US Approved OTC ,21 CFR 341.12(e) cough/cold:antihistamine dexchlorpheniramine maleate,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec341-12.xml,US Previously Marketed 1958,Polaramine by Schering,DeHaen 1940-1975 NMEs,Allergy,Approved
196,138530-94-6,https://drugs.ncats.io/drug/UYE4T5I70X,US Approved Rx 2012,ANDA202176,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202176,US Approved Rx 1995,NDA020406,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020406,Active duodenal ulcer; Gastric ulcer; Gastroesophageal reflux disease; Erosive esophagitis; Heartburn; Gastroesophageal reflux disease; Active duodenal ulcer; Gastric ulcer,Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved
197,113775-47-6,https://drugs.ncats.io/drug/67VB76HONO,US Approved Rx 2018,ANDA206798,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206798,US Approved Rx 1999,NDA021038,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021038,Pain,Approved
198,40431-64-9,https://drugs.ncats.io/drug/M32RH9MFGP,US Approved Rx 2015,ANDA201231,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201231,US Approved Rx 2001,NDA021278,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021278,Attention deficit hyperactivity disorder,Approved
199,81-13-0,https://drugs.ncats.io/drug/1O6C93RI7Z,US Approved Rx 2000,NDA021163,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021163,US Previously Marketed 1947,BEROCCA PN by ROCHE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=006071,Skin moisturizer; SUNBURN,Basic research; Approved
200,24584-09-6,https://drugs.ncats.io/drug/048L81261F,US Approved Rx 2011,ANDA200752,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=200752,US Previously Marketed 1995,Zinecard,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=20212,Breast cancer,Approved
201,9004-54-0,https://drugs.ncats.io/drug/ZNJ8R24I7Z,,,,,,,,
202,56087-11-7,https://drugs.ncats.io/drug/30KXI0TVD3,Possibly Marketed Outside US ,WHO-ATC:D03AX02,https://ginas.ncats.nih.gov/ginas/app/substance/30KXI0TVD3,,,,,
203,9004-53-9,https://drugs.ncats.io/drug/ODU3ZAZ94J,US Approved Rx 2023,NDA216386,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216386,US Approved Rx 2023,NDA216386,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216386,,
204,125-71-3,https://drugs.ncats.io/drug/7355X3ROTS,US Approved OTC ,21 CFR 341.14(a)(4) cough/cold:antitussive dextromethorphan hydrobromide,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec341-14.xml,US Previously Marketed 1954,Romilar by Hoffmann-La Roche,OB NME Appendix 1950-1985,Cough; Pseudobulbar affect,Approved; Approved
205,469-62-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
206,51-49-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
207,117-96-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
208,439-14-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
209,78491-02-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
210,364-98-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
211,480-30-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
212,79-43-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
213,75-71-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
214,15307-86-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
215,120-97-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
216,3116-76-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
217,66-76-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
218,77-19-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
219,69655-05-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
220,13029-44-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
221,65928-58-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
222,56-53-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
223,134-62-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
224,28782-42-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
225,2557-49-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
226,22494-42-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
227,23674-86-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
228,71-63-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
229,20830-75-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
230,125-28-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
231,1847-58-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
232,115256-11-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
233,115956-12-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
234,60937-55-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
235,1051375-16-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
236,13900-14-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
237,57808-66-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
238,120014-06-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
239,51-61-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
240,864821-90-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
241,697761-98-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
242,1709815-23-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
243,87233-61-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
244,1610943-06-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
245,56-81-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
246,864070-44-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
247,143491-57-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
248,75847-73-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
249,76420-72-9,https://drugs.ncats.io/drug/Q508Q118JM,US Approved Rx 2001,ANDA075727,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=075727,US Approved Rx 1985,NDA018998,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018998,Hypertension; Asymptomatic left ventricular dysfunction; Heart failure,Approved; Approved; Approved
250,1446502-11-9,https://drugs.ncats.io/drug/3T1SS4E7AG,US Approved Rx 2017,NDA209606,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209606,US Approved Rx 2017,NDA209606,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209606,Acute myeloid leukemia; acute myeloid leukemia,Phase III; Approved
251,1269440-17-6,https://drugs.ncats.io/drug/8L7891MRB6,US Approved Rx 2018,NDA210496,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210496,US Approved Rx 2018,NDA210496,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210496,Melanoma; Metastatic colorectal cancer; Relapsed or refractory multiple myeloma,Approved; Phase III; Phase II
252,13838-16-9,https://drugs.ncats.io/drug/91I69L5AY5,US Previously Marketed 1987,ENFLURANE by ABBOTT,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=070803,US Previously Marketed 1972,ETHRANE by BAXTER HLTHCARE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017087,Pain,Approved
253,159519-65-0,https://drugs.ncats.io/drug/19OWO1T3ZE,US Approved Rx 2003,NDA021481,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021481,US Approved Rx 2003,NDA021481,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021481,HIV-1 infection,Approved
254,74011-58-8,https://drugs.ncats.io/drug/325OGW249P,US Previously Marketed 1991,PENETREX by SANOFI AVENTIS US,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019616,US Previously Marketed 1991,PENETREX by SANOFI AVENTIS US,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019616,"Uncomplicated urethral or cervical gonorrhea due to Neisseria gonorrhoeae.; Complicated urinary tract infections; Uncomplicated urinary tract infections (cystitis) due to Escherichia coli, Staphylococcus epidermidis, or Staphylococcus saprophyticus",Approved; Approved; Approved
255,679809-58-6,https://drugs.ncats.io/drug/8NZ41MIK1O,US Approved Rx 2014,ANDA076726,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=076726,US Approved Rx 1993,NDA020164,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020164,Deep vein thrombosis; Myocardial infarction; Unstable angina,Approved; Approved; Approved
256,471-53-4,https://drugs.ncats.io/drug/P540XA09DR,US Previously Marketed 1921,Ammoniated Glycyrrhizin U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,US Previously Marketed 1921,Ammoniated Glycyrrhizin U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Hepatitis B; Autoimmune hepatitis; Chronic hepatitis C; Chronic hepatitis C; Erythema; Cardiomyopathy; Autoimmune hepatitis; Ovarian cancer; Radiodermatitis; Leukemia; Unknown; Unknown; Inflammation,Not Provided; Phase I; Not Provided; Approved; Phase I; Preclinical; Phase I; Basic research; Basic research; Basic research; Basic research
257,93106-60-6,https://drugs.ncats.io/drug/3DX3XEK1BN,Possibly Marketed Outside US ,Canada:ENROFLOXACIN,https://tripod.nih.gov/npc/#Download,Possibly Marketed Outside US 1988,NADA140441,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e6228e80-a92a-4c24-8a0b-10bd0aff53db,Bacterial infections,Approved
258,130929-57-6,https://drugs.ncats.io/drug/4975G9NM6T,US Approved Rx 2017,ANDA207210,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207210,US Approved Rx 1999,NDA020796,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020796,Parkinson's disease,Approved
259,142217-69-4,https://drugs.ncats.io/drug/NNU2O4609D,US Approved Rx 2018,ANDA208721,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208721,US Approved Rx 2005,NDA021798,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021798,Hepatitis B,Approved
260,915087-33-1,https://drugs.ncats.io/drug/93T0T9GKNU,US Approved Rx 2020,NDA213674,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213674,US Approved Rx 2012,NDA203415,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203415,Castrate-resistant prostate cancer,Approved
261,299-42-3,https://drugs.ncats.io/drug/GN83C131XS,US Approved OTC ,21 CFR 341.20(b)(3) cough/cold:nasal decongestant ephedrine hydrochloride,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec341-20.xml,US Previously Marketed 1928,Ephetonine by Merck,https://www.google.com/books/edition/American_Journal_of_Pharmacy/NEAfAQAAIAAJ?hl=en&gbpv=1&bsq=ephetonine&dq=ephetonine&printsec=frontcover,Anesthesia-induced hypotension,Approved
262,989-51-5,https://drugs.ncats.io/drug/BQM438CTEL,Possibly Marketed Outside US 2023,21 CFR 341,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00f8f724-87bc-e3f5-e063-6394a90a2eed,Possibly Marketed Outside US 2012,BabySpaShea Butter Diaper by EXPRO3 LLC,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=15c9f3c4-833a-4211-a0d0-31e754e7fb9f,Multiple sclerosis; Multiple system atrophy; Duchenne muscular dystrophy,Phase III; Phase III; Phase III
263,80012-43-7,https://drugs.ncats.io/drug/Q13WX941EF,US Approved Rx 2011,ANDA090870,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=090870,US Previously Marketed 2003,ELESTAT by ALLERGAN,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021565,Allergic conjunctivitis,Approved
264,51-43-4,https://drugs.ncats.io/drug/YKH834O4BH,US Approved OTC ,21 CFR 346.12(c) anorectal:vasoconstrictor epinephrine hydrochloride,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec346-12.xml,US Previously Marketed 1901,Adrenalin by Parke Davis,https://babel.hathitrust.org/cgi/pt?id=mdp.39015064545372&view=1up&seq=65,Miosis; Anaphylaxis,Approved; Approved
265,56420-45-2,https://drugs.ncats.io/drug/3Z8479ZZ5X,US Approved Rx 2009,ANDA090163,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=090163,US Approved Rx 1999,NDA050778,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050778,,
266,107724-20-9,https://drugs.ncats.io/drug/6995V82D0B,US Approved Rx 2018,ANDA208283,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208283,US Approved Rx 2002,NDA021437,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021437,Hypertension,Approved
267,11096-26-7,https://drugs.ncats.io/drug/64FS3BFH5W,US Approved Rx 2018,BLA125545,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125545,US Approved Rx 1989,BLA103234,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103234,,
268,11096-26-7,https://drugs.ncats.io/drug/64FS3BFH5W,US Approved Rx 2018,BLA125545,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125545,US Approved Rx 1989,BLA103234,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103234,,
269,35121-78-9,https://drugs.ncats.io/drug/DCR9Z582X0,US Approved Rx 2008,NDA022260,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022260,US Approved Rx 1995,NDA020444,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020444,Primary pulmonary hypertension,Approved
270,133040-01-4,https://drugs.ncats.io/drug/2KH13Z0S0Y,US Previously Marketed 2001,TEVETEN HCT by ABBVIE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021268,US Previously Marketed 1997,TEVETEN by ABBVIE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020738,Hypertension,Approved
271,188627-80-7,https://drugs.ncats.io/drug/NA8320J834,US Approved Rx 2015,ANDA206127,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206127,US Previously Marketed 1998,INTEGRILIN by MSD SUB MERCK,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020718,Acute coronary syndrome,Approved
272,1207283-85-9,https://drugs.ncats.io/drug/07896928ZC,US Approved Rx 2018,NDA211109,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211109,US Approved Rx 2018,NDA211109,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211109,Intra-abdominal infections,Approved
273,1582205-90-0,https://drugs.ncats.io/drug/I5I8VB78VT,US Approved Rx 2018,BLA761077,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761077,US Approved Rx 2018,BLA761077,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761077,,
274,50-14-6,https://drugs.ncats.io/drug/VS041H42XC,US Approved Rx 1941,NDA003444,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=003444,US Approved Rx 1941,NDA003444,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=003444,Hypoparathyroidism; Familial hypophosphatemia; Refractory rickets,Approved; Approved; Approved
275,60-79-7,https://drugs.ncats.io/drug/WH41D8433D,US Previously Marketed 1959,TACE 25 MG ERGONOVINE by MERRELL,https://www.govinfo.gov/content/pkg/FR-1998-12-17/pdf/98-33453.pdf,US Previously Marketed 1959,TACE 25 MG ERGONOVINE by MERRELL,https://www.govinfo.gov/content/pkg/FR-1998-12-17/pdf/98-33453.pdf,Postpartum haemorrhage; Postabortion haemorrhage,Approved; Approved
276,113-15-5,https://drugs.ncats.io/drug/PR834Q503T,US Approved Rx 1983,ANDA086557,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=086557,US Previously Marketed 1948,CAFERGOT by NOVARTIS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=006620,Migraine; Migraine; Migraine,Approved; Approved; Approved
277,253128-41-5,https://drugs.ncats.io/drug/LR24G6354G,US Approved Rx 2010,NDA201532,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201532,US Approved Rx 2010,NDA201532,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201532,Breast Cancer,Approved
278,183321-74-6,https://drugs.ncats.io/drug/J4T82NDH7E,US Approved Rx 2014,ANDA091002,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=091002,US Previously Marketed 2004,TARCEVA by OSI PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021743,"Locally advanced or metastatic non-small cell lung cancer; Locally advanced, unresectable or metastatic pancreatic cancer",Approved; Approved
279,153832-46-3,https://drugs.ncats.io/drug/G32F6EID2H,US Approved Rx 2018,ANDA208790,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208790,US Approved Rx 2001,NDA021337,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021337,"Complicated intra-abdominal infections; Complicated skin and skin structure infections; Community acquired pneumonia; Complicated urinary tract infections including pyelonephritis; Acute pelvic infections including postpartum endomyometritis, septic abortion and post surgical gynecologic infections",Approved; Approved; Approved; Approved; Approved
280,119683-68-0,https://drugs.ncats.io/drug/G6N3J05W84,US Approved Rx 2009,NDA022180,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022180,Possibly Marketed Outside US 1995,ANDA065520,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e1904c28-8c19-44da-b395-1e4bd08d6122,Acne,Approved
281,171544-35-7,https://drugs.ncats.io/drug/6HJV9H13XS,US Previously Marketed 1996,GASTROMARK by AMAG PHARMS INC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020410,US Previously Marketed 1996,GASTROMARK by AMAG PHARMS INC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020410,,
282,1309-38-2,https://drugs.ncats.io/drug/XM0M87F357,US Approved Rx 2009,NDA022180,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022180,Possibly Marketed Outside US 1995,ANDA065520,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e1904c28-8c19-44da-b395-1e4bd08d6122,Acne,Approved
283,286930-02-7,https://drugs.ncats.io/drug/621G617227,US Approved Rx 2023,ANDA204973,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204973,US Approved Rx 2008,NDA022030,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022030,Overactive bladder; Urinary incontinence; Partial urethral obstruction; Overactive bladder,Approved; Preclinical; Preclinical; Approved
284,83799-24-0,https://drugs.ncats.io/drug/E6582LOH6V,US Approved Rx 2012,ANDA091567,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=091567,US Previously Marketed 1996,ALLEGRA by CHATTEM SANOFI,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020625,Seasonal allergic rhinitis,Approved
285,25878-23-3,https://drugs.ncats.io/drug/82FOM4R7CD,,,,,,,,
286,873857-62-6,https://drugs.ncats.io/drug/Z5N076G8YQ,US Approved Rx 2024,ANDA208443,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208443,US Approved Rx 2011,NDA201699,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201699,Clostridium difficile-associated diarrhea,Approved
287,121181-53-1,https://drugs.ncats.io/drug/PVI5M0M1GW,US Approved Rx 1991,BLA103353,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103353,US Approved Rx 1991,BLA103353,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103353,,
288,98319-26-7,https://drugs.ncats.io/drug/57GNO57U7G,US Approved Rx 2006,ANDA076511,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=076511,US Approved Rx 1992,NDA020180,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020180,Androgenic alopecia; Benign prostatic hyperplasia,Approved; Approved
289,356-12-7,https://drugs.ncats.io/drug/2W4A77YPAN,US Approved Rx 2020,ANDA208989,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208989,US Previously Marketed 1971,LIDEX by ALVOGEN,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016909,Corticosteroid-responsive dermatoses,Approved
290,2321-07-5,https://drugs.ncats.io/drug/TPY09G7XIR,US Approved Rx 2023,ANDA215709,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215709,Possibly Marketed Outside US 1958,NDA208742,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7514e6b8-c33f-4fbf-8810-ef520e1eb4bd,Fluorescein angiography or angioscopy of the retina vasculature; Fluorescein angiography or angioscopy of the iris vasculature,Approved; Approved
291,7782-41-4,https://drugs.ncats.io/drug/284SYP0193,Clinical 2021,NCT04705428: Not Applicable Interventional Completed White Spot Lesion,https://clinicaltrials.gov/ct2/show/NCT04705428,,,,,
292,426-13-1,https://drugs.ncats.io/drug/SV0CSG527L,US Approved Rx 1972,NDA016851,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016851,US Previously Marketed 1959,Oxylone Cream by Upjohn,OB NME Appendix 1950-1993,"Inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe",Approved
293,51-21-8,https://drugs.ncats.io/drug/U3P01618RT,US Approved Rx 1998,ANDA040278,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=040278,US Previously Marketed 1962,FLUOROURACIL by SPECTRUM PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012209,Prostate cancer; Lung cancer; Breast cancer; Head and neck cancer; Digestive system neoplasms; Breast adenocarcinoma; Gastric adenocarcinoma; Adenocarcinoma of the colon,Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved
294,54910-89-3,https://drugs.ncats.io/drug/01K63SUP8D,US Approved Rx 2001,ANDA075049,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=075049,US Approved Rx 1987,NDA018936,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018936,Obsessive-compulsive disorder; Panic disorder; Bulimia nervosa; Major depressive disorder,Approved; Approved; Approved; Approved
295,76-43-7,https://drugs.ncats.io/drug/9JU12S4YFY,US Previously Marketed 1983,FLUOXYMESTERONE by WATSON LABS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=088309,US Previously Marketed 1956,HALOTESTIN by PHARMACIA AND UPJOHN,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=010611,Male hypogonadism; Delayed male puberty; Inoperable metastatic female breast cancer,Approved; Approved; Approved
296,69-23-8,https://drugs.ncats.io/drug/S79426A41Z,US Approved Rx 2023,ANDA217410,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217410,US Previously Marketed 1959,PROLIXIN by APOTHECON,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012145,Schizophrenia,Approved
297,17617-23-1,https://drugs.ncats.io/drug/IHP475989U,US Approved Rx 1989,ANDA072368,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=072368,US Previously Marketed 1970,DALMANE by VALEANT PHARM INTL,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016721,Insomnia,Approved
298,5104-49-4,https://drugs.ncats.io/drug/5GRO578KLP,US Approved Rx 1995,ANDA074447,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=074447,US Previously Marketed 1986,OCUFEN by ALLERGAN,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019404,Osteoarthritis; Rheumatoid arthritis; Osteoarthritis,Approved; Approved; Approved
299,13311-84-7,https://drugs.ncats.io/drug/76W6J0943E,US Approved Rx 2001,ANDA075298,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=075298,US Previously Marketed 1989,EULEXIN by SCHERING,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018554,Metastatic carcinoma of the prostate,Approved
300,90566-53-3,https://drugs.ncats.io/drug/CUT2W21N7U,Possibly Marketed Outside US ,WHO-ATC:D07AC17,https://ginas.ncats.nih.gov/ginas/app/substance/CUT2W21N7U,,,,,
301,397864-44-7,https://drugs.ncats.io/drug/JS86977WNV,US Approved Rx 2007,NDA022051,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022051,US Approved Rx 2007,NDA022051,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022051,Asthma; Chronic obstructive pulmonary disease; Perennial or seasonal allergic rhinitis,Approved; Approved; Approved
302,93957-54-1,https://drugs.ncats.io/drug/4L066368AS,US Approved Rx 2012,ANDA078407,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=078407,US Previously Marketed 1993,LESCOL by NOVARTIS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020261,Hypercholesterolemia; Atherosclerosis; Dyslipidemia,Approved; Approved; Approved
303,54739-18-3,https://drugs.ncats.io/drug/O4L1XPO44W,US Approved Rx 2013,ANDA091476,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=091476,US Previously Marketed 1994,LUVOX by SOLVAY,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020243,Obsessive-compulsive disorder,Approved
304,59-30-3,https://drugs.ncats.io/drug/935E97BOY8,US Approved Rx 2005,ANDA040625,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=040625,US Previously Marketed 1946,FOLVRON by LEDERLE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=006012,Megaloblastic anemia,Approved
305,97048-13-0,https://drugs.ncats.io/drug/W9BB98U6HP,US Approved Rx 2002,BLA021484,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021484,US Previously Marketed 1986,METRODIN by SERONO,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019415,,
306,146479-72-3,https://drugs.ncats.io/drug/2M2GGL7HUP,Possibly Marketed Outside US ,Puregon by Merck Ltd. [Canada],https://www.drugbank.ca/drugs/DB00066,,,,,
307,146479-72-3,https://drugs.ncats.io/drug/2M2GGL7HUP,Possibly Marketed Outside US ,Puregon by Merck Ltd. [Canada],https://www.drugbank.ca/drugs/DB00066,,,,,
308,7554-65-6,https://drugs.ncats.io/drug/83LCM6L2BY,US Approved Rx 2023,ANDA216791,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216791,US Previously Marketed 1997,ANTIZOL by PAR PHARM INC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020696,Ethylene glycol Poisoning,Approved
309,160369-77-7,https://drugs.ncats.io/drug/3Z6W3S36X5,US Previously Marketed 1998,VITRAVENE PRESERVATIVE FREE by NOVARTIS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020961,US Previously Marketed 1998,VITRAVENE PRESERVATIVE FREE by NOVARTIS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020961,,
310,114870-03-0,https://drugs.ncats.io/drug/X0Q6N9USOZ,US Approved Rx 2018,ANDA208615,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208615,US Approved Rx 2001,NDA021345,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021345,Deep Vein Thrombosis,Approved
311,50-00-0,https://drugs.ncats.io/drug/T0H3L6C7I5,Possibly Marketed Outside US 2019,HB Triple Play by Wausau Chemical,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=426419d4-5d88-438c-9c10-2541abb6a3fc,Possibly Marketed Outside US 2019,HB Triple Play by Wausau Chemical,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=426419d4-5d88-438c-9c10-2541abb6a3fc,,
312,64-18-6,https://drugs.ncats.io/drug/0YIW783RG1,US Previously Marketed 1921,Formic Acid N.F.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,US Previously Marketed 1921,Formic Acid N.F.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Warts,Approved
313,73573-87-2,https://drugs.ncats.io/drug/5ZZ84GCW8B,US Approved Rx 2022,ANDA211699,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211699,US Previously Marketed 2001,FORADIL by NOVARTIS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020831,Asthma; Chronic obstructive pulmonary disease,Approved; Approved
314,226700-79-4,https://drugs.ncats.io/drug/WOU1621EEG,US Approved Rx 2016,ANDA204060,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204060,US Previously Marketed 1999,AGENERASE by GLAXOSMITHKLINE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021039,HIV-1 infection,Approved
315,172673-20-0,https://drugs.ncats.io/drug/6L8OF9XRDC,US Approved Rx 2008,NDA022023,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022023,US Approved Rx 2003,NDA021549,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021549,Postoperative nausea and vomiting; Chemotherapy induced nausea and vomiting; Chemotherapy induced nausea and vomiting; Postoperative nausea and vomiting,Approved; Approved; Approved; Approved
316,63585-09-1,https://drugs.ncats.io/drug/8C5OQ81LWT,US Approved Rx 2021,ANDA212483,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212483,US Approved Rx 1991,NDA020068,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020068,Cytomegalovirus retinitis,Approved
317,522-40-7,https://drugs.ncats.io/drug/A0E0NMA80F,US Previously Marketed 1982,DIETHYLSTILBESTROL by LILLY,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=004040,US Previously Marketed 1941,Diethylstilbestrol by Various Mfrs.,DeHaen 1940-1975 NMEs,Prostate cancer; Prostate cancer; Miscarriage; Atrophic vaginitis; Vulvar dystrophy; Amenorrhea; Female hypogonadism; Postmenopausal osteoporosis; Menopausal syndrome,Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved
318,77-86-1,https://drugs.ncats.io/drug/023C2WHX2V,US Previously Marketed 1965,THAM-E by HOSPIRA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=013025,US Previously Marketed 1965,THAM-E by HOSPIRA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=013025,Metabolic acidosis,Approved
319,98048-97-6,https://drugs.ncats.io/drug/R43D2573WO,US Approved Rx 2009,ANDA079245,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=079245,US Previously Marketed 1991,MONOPRIL by BRISTOL MYERS SQUIBB,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019915,Hypertension,Approved
320,93390-81-9,https://drugs.ncats.io/drug/B4SF212641,US Approved Rx 2006,ANDA040684,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=040684,US Previously Marketed 1938,Dilantin by Parke-Davis,http://triggered.edina.clockss.org/ServeContent?rft_id=info:doi/10.1124/mi.9.5.1,Seizures; Status epilepticus,Approved; Approved
321,258516-89-1,https://drugs.ncats.io/drug/LZ257RZP7K,US Approved Rx 2018,ANDA205067,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205067,US Approved Rx 1989,NDA019627,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019627,Pain,Approved
322,901119-35-5,https://drugs.ncats.io/drug/SQ8A3S5101,US Approved Rx 2018,NDA209299,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209299,US Approved Rx 2018,NDA209299,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209299,Rheumatoid arthritis; Immune thrombocytopenia; Autoimmune hemolytic anemia; IgA nephropathy; Ovarian cancer,Phase III; Approved; Phase II; Phase II; Phase I
323,1655501-53-3,https://drugs.ncats.io/drug/PF8K38CG54,US Approved Rx 2018,BLA761089,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761089,US Approved Rx 2018,BLA761089,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761089,,
324,158747-02-5,https://drugs.ncats.io/drug/H82Q2D5WA7,US Approved Rx 2022,ANDA213891,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213891,US Approved Rx 2001,NDA021006,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021006,Migraine without aura; Migraine with aura,Approved; Approved
325,6347-01-9,https://drugs.ncats.io/drug/6YSS42VSEV,US Previously Marketed 1953,Levugen by Mead Johnson,DeHaen 1940-1975 NMEs,US Previously Marketed 1921,fructose,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Pain,Approved
326,3351-86-8,https://drugs.ncats.io/drug/06O0TC0VSM,Clinical 2019,"NCT03613740: Phase 2 Interventional Active, not recruiting Metabolic Syndrome",https://clinicaltrials.gov/ct2/show/NCT03613740,,,,Cancer; Non-alcoholic fatty liver disease; Alzheimer’s disease,Preclinical; Not Provided; Preclinical
327,977001-75-4,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
328,129453-61-8,https://drugs.ncats.io/drug/22X328QOC4,US Approved Rx 2019,ANDA205935,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205935,US Approved Rx 2002,NDA021344,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021344,Hormone receptor positive metastatic breast cancer,Approved
329,110-17-8,https://drugs.ncats.io/drug/88XHZ13131,US Approved Rx 2019,NDA211855,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211855,Possibly Marketed Outside US 1946,NDA006035,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1552d48-86f5-4184-810a-001e57e96c02,Arthritis; Multiple sclerosis; Ischemic stroke; Cancer; Periapical diseases; Unknown; Relapsing forms of multiple sclerosis; Unknown,Preclinical; Approved; Preclinical; Natural Metabolite; Not Provided; Approved
330,7440-57-5,https://drugs.ncats.io/drug/79Y1949PYO,Possibly Marketed Outside US ,Canada:AURUM MURIATICUM,https://tripod.nih.gov/npc/#Download,Possibly Marketed Outside US 2002,NDA207202,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8787c3f-5e41-42d1-8091-44b56346620f,,
331,476181-74-5,https://drugs.ncats.io/drug/91X1KLU43E,US Approved Rx 2009,BLA125289,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125289,US Approved Rx 2009,BLA125289,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125289,,
332,9034-40-6,https://drugs.ncats.io/drug/9O7312W37G,US Previously Marketed 1982,FACTREL by HIKMA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018123,Possibly Marketed Outside US 1978,NADA098379,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cddeff5b-ba19-4d92-8f91-8a6238f89c98,Hypogonadism; Amenorrhea,Approved; Approved
333,65807-02-5,https://drugs.ncats.io/drug/0F65R8P09N,US Approved Rx 1996,NDA020578,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020578,US Approved Rx 1989,NDA019726,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019726,Advanced carcinoma of the prostate; Locally confined carcinoma of the prostate,Approved; Approved
334,1405-97-6,https://drugs.ncats.io/drug/5IE62321P4,US Approved Rx 1968,ANDA060582,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=060582,US Previously Marketed 1949,Gramoderm by Schering,DeHaen 1940-1975 NMEs,,
335,109889-09-0,https://drugs.ncats.io/drug/WZG3J2MCOL,US Approved Rx 2009,ANDA078531,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=078531,US Previously Marketed 1993,KYTRIL by ROCHE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020239,Nausea and vomiting associated with emetogenic chemotherapy,Approved
336,7782-42-5,https://drugs.ncats.io/drug/4QQN74LH4O,Possibly Marketed Outside US ,Canada:GRAPHITE,https://tripod.nih.gov/npc/#Download,Possibly Marketed Outside US 2023,Herpes Relief Cream by Ehy Holdings LLC,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f209ee77-d290-1203-e053-2a95a90adb8c,,
337,1350514-68-9,https://drugs.ncats.io/drug/8YE81R1X1J,US Approved Rx 2016,NDA208261,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208261,US Approved Rx 2016,NDA208261,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208261,Hepatitis C,Approved
338,119914-60-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
339,126-07-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
340,90-05-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
341,93-14-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
342,64-17-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
343,51-45-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
344,71-00-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
345,9008-05-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
346,76712-82-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
347,87-00-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
348,118-56-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
349,8028-66-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
350,9041-92-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
351,61489-71-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
352,6754-58-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
353,102518-79-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
354,9004-61-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
355,9001-54-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
356,461-72-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
357,86-54-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
358,7647-01-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
359,58-93-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
360,125-29-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
361,50-23-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
362,72590-77-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
363,135-09-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
364,7722-84-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
365,466-99-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
366,123-31-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
367,13422-51-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
368,103-86-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
369,127-07-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
370,118-42-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
371,9004-62-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
372,1190-94-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
373,68-96-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
374,618-28-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
375,83-40-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
376,68-88-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
377,101-31-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
378,548-04-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
379,7790-92-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
380,680188-33-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
381,114084-78-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
382,206181-63-7,https://drugs.ncats.io/drug/4Q52C550XK,US Approved Rx 2002,BLA125019,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125019,US Approved Rx 2002,BLA125019,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125019,,
383,936563-96-1,https://drugs.ncats.io/drug/1X70OSD4VX,US Approved Rx 2022,NDA217003,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217003,US Approved Rx 2013,NDA205552,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205552,Waldenström's macroglobulinemia; Mantle cell lymphoma; Chronic lymphocytic leukemia,Approved; Approved; Approved
384,15687-27-1,https://drugs.ncats.io/drug/WK2XYI10QM,US Approved Rx 1987,ANDA072096,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=072096,US Previously Marketed 1974,MOTRIN by MCNEIL CONSUMER,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017463,Headache; Common cold; Backache; Toothache; Muscular aches,Approved; Approved; Approved; Approved; Approved
385,2276-90-6,https://drugs.ncats.io/drug/16CHD79MIX,US Approved Rx 1962,NDA013295,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=013295,US Approved Rx 1962,NDA013295,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=013295,Kidney failure,Approved
386,87771-40-2,https://drugs.ncats.io/drug/N3RIB7X24K,US Approved Rx 1988,NDA019710,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019710,US Approved Rx 1988,NDA019710,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019710,Urinary system disease; Cardiovascular diseases; Glioma,Approved; Approved; Approved
387,59017-64-0,https://drugs.ncats.io/drug/Z40X7EI2AF,US Previously Marketed 1985,HEXABRIX by GUERBET,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018905,US Previously Marketed 1985,HEXABRIX by GUERBET,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018905,Vascular cerebral disorders; Joint disorder; Coronary artery disease; Urinary tract disorders; Vein disease; Kidney failure; Brain disease; Coronary artery disease,Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved
388,107793-72-6,https://drugs.ncats.io/drug/A4YJ7J11TG,US Previously Marketed 1995,OXILAN-300 by GUERBET,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020316,US Previously Marketed 1995,OXILAN-300 by GUERBET,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020316,Contrast agent,Approved
389,477202-00-9,https://drugs.ncats.io/drug/6T8C155666,US Approved Rx 2011,BLA125377,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125377,US Approved Rx 2011,BLA125377,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125377,,
390,22254-24-6,https://drugs.ncats.io/drug/VJV4X1P2Z1,US Approved Rx 2003,ANDA076025,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=076025,US Previously Marketed 1986,ATROVENT by BOEHRINGER INGELHEIM,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019085,Chronic obstructive pulmonary disease,Approved
391,138402-11-6,https://drugs.ncats.io/drug/J0E2756Z7N,US Approved Rx 2012,ANDA077369,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=077369,US Approved Rx 1997,NDA020758,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020758,Hypertension; Diabetic nephropathy,Approved; Approved
392,97682-44-5,https://drugs.ncats.io/drug/7673326042,,,,,,,,
393,9004-66-4,https://drugs.ncats.io/drug/95HR524N2M,US Approved OTC ,21 CFR 347.10(c) skin protectant calamine,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec347-10.xml,US Previously Marketed 1921,Saccharated Ferric Oxide N.F.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Iron deficiency anemia; Radioactive cesium and/or radioactive or non-radioactive thallium internal contamination; Pain; Unknown; Chronic kidney disease; Unknown; Unknown; Unknown; Dental diseases; Parenteral Nutrition; Iron deficiency,Approved; Approved; Approved; Approved; Basic research; Approved; Approved
394,7705-08-0,https://drugs.ncats.io/drug/U38V3ZVV3V,US Approved OTC ,21 CFR 347.10(c) skin protectant calamine,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec347-10.xml,US Previously Marketed 1921,Saccharated Ferric Oxide N.F.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Iron deficiency anemia; Radioactive cesium and/or radioactive or non-radioactive thallium internal contamination; Pain; Unknown; Chronic kidney disease; Unknown; Unknown; Unknown; Dental diseases; Parenteral Nutrition; Iron deficiency,Approved; Approved; Approved; Approved; Basic research; Approved; Approved
395,59-01-8,https://drugs.ncats.io/drug/EQK9Q303C5,US Previously Marketed 2002,KANAMYCIN SULFATE by FRESENIUS KABI USA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=065111,US Previously Marketed 1958,Kantrex by Bristol,DeHaen 1940-1975 NMEs,Unknown,
396,1332-58-7,https://drugs.ncats.io/drug/24H4NWX5CO,US Approved OTC ,21 CFR 335.10(b) antidiarrheal kaolin,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec335-10.xml,US Previously Marketed 1921,Kaolin N.F.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Diaper rash; Ulcerative colitis; Radiation- and chemotherapy-induced mucositis; Diarrhea; Cholera,Approved; Approved; Approved; Approved; Approved
397,8008-20-6,https://drugs.ncats.io/drug/1C89KKC04E,,,,,,,,
398,6740-88-1,https://drugs.ncats.io/drug/690G0D6V8H,US Approved Rx 1996,ANDA074549,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=074549,US Approved Rx 1970,NDA016812,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016812,Pain,Approved
399,65277-42-1,https://drugs.ncats.io/drug/R9400W927I,US Approved Rx 2000,ANDA075581,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=075581,US Previously Marketed 1981,NIZORAL by JANSSEN PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018533,Tinea corporis; Tinea pedis; Cutaneous candidiasis; Blastomycosis; Coccidioidomycosis; Cushing’s disease; Type 2 diabetes mellitus,Approved; Approved; Approved; Approved; Approved; Phase III; Phase II
400,22071-15-4,https://drugs.ncats.io/drug/90Y4QC304K,US Approved Rx 1993,ANDA074014,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=074014,US Previously Marketed 1986,ORUDIS by WYETH AYERST,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018754,"Rheumatoid arthritis; Pain; Osteoarthritis; Primary dysmenorrhea; Migraine; Pain, postoperative; Musculoskeletal pain",Approved; Approved; Approved; Approved; Approved; Approved; Approved
401,74103-06-3,https://drugs.ncats.io/drug/YZI5105V0L,US Approved Rx 2009,ANDA077308,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=077308,US Previously Marketed 1989,TORADOL by ROCHE PALO,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019698,Ocular pain,Approved
402,34580-13-7,https://drugs.ncats.io/drug/X49220T18G,US Approved Rx 2008,ANDA077200,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=077200,US Previously Marketed 1999,ZADITOR by ALCON PHARMA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021066,Allergic conjunctivitis,Approved
403,501-30-4,https://drugs.ncats.io/drug/6K23F1TT52,Possibly Marketed Outside US 2024,505G(a)(3),https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10c878ed-c1d6-5948-e063-6294a90a5bac,Possibly Marketed Outside US 2002,21 CFR 358,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c24a9fd8-1fb5-4643-92df-b268479a35e5,Hyperpigmentation,Preclinical
404,63-68-3,https://drugs.ncats.io/drug/AE28F7PNPL,US Previously Marketed 1945,Methionine by Various Mfrs.,DeHaen 1940-1975 NMEs,US Previously Marketed 1945,Methionine by Various Mfrs.,DeHaen 1940-1975 NMEs,AIDS vacuolar myelopathy; Skin irritation in incontinent adults and diaper rash in infants; Alkaline urine,Phase III; Not Provided; Approved
405,36894-69-6,https://drugs.ncats.io/drug/R5H8897N95,US Approved Rx 2018,ANDA209603,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209603,Possibly Marketed Outside US 1984,NDA018716,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a4195473-51a9-40f1-8678-1478ebca2d84,Hypertension,Approved
406,175481-36-4,https://drugs.ncats.io/drug/563KS2PQY5,US Approved Rx 2023,ANDA215379,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215379,US Approved Rx 2008,NDA022254,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022254,Partial-onset seizures; Diabetic neuropathy,Approved; Phase III
407,68333-16-4,https://drugs.ncats.io/drug/1PRR1V42V5,US Previously Marketed 1921,Lactobacillus acidophilus,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,US Previously Marketed 1921,Lactobacillus acidophilus,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,,
408,68333-14-2,https://drugs.ncats.io/drug/SA940P2U00,Possibly Marketed Outside US ,Canada:LACTOBACILLUS CASEI,https://tripod.nih.gov/npc/#Download,Possibly Marketed Outside US 2013,Fusion Plus by U.S. Pharmaceutical Corporation,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1c692970-41fc-47a9-a0ff-67b9d41ab217,,
409,81103-11-9,https://drugs.ncats.io/drug/H1250JIK0A,US Approved Rx 1993,NDA050697,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050697,US Previously Marketed 1991,BIAXIN by ABBVIE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050662,Community-acquired pneumonia; Uncomplicated skin and skin-structure infections; Disseminated mycobacterial infections; Bacterial pharyngitis; Bacterial tonsillitis; Acute bacterial maxillary sinusitis; Acute bacterial exacerbation of chronic bronchitis; Helicobacter pylori infection; Acute bacterial otitis media,Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved
410,5965-66-2,https://drugs.ncats.io/drug/13Q3A43E0S,,,,,,,,
411,4618-18-2,https://drugs.ncats.io/drug/9U7D5QH5AE,US Approved Rx 2003,ANDA076645,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=076645,Possibly Marketed Outside US 1966,ANDA074623,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f19e4ed-c90a-4330-a7fa-bf911aa98f09,Chronic constipation; Portal-systemic encephalopathy,Approved; Approved
412,4547-24-4,https://drugs.ncats.io/drug/AMX2I57A98,,,,,,,Type 2 diabetes mellitus,Basic research
413,134678-17-4,https://drugs.ncats.io/drug/2T8Q726O95,US Approved Rx 1998,NDA021004,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021004,US Approved Rx 1995,NDA020564,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020564,HIV-1 infection; Chronic hepatitis B; Unknown,Approved; Approved
414,84057-84-1,https://drugs.ncats.io/drug/U3H27498KS,US Approved Rx 2015,ANDA204158,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204158,US Approved Rx 1994,NDA020241,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020241,Epilepsy; Bipolar disorder,Approved; Approved
415,1426055-14-2,https://drugs.ncats.io/drug/2372V1TKXK,Possibly Marketed Outside US ,Takhzyro by Shire Pharma Canada Ulc [Canada],https://www.drugbank.ca/drugs/DB14597,Possibly Marketed Outside US 2018,BLA761090,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=15f99d8c-efe7-4f7d-aa20-0d0f1e30c6e8,,
416,108736-35-2,https://drugs.ncats.io/drug/0G3DE8943Y,US Approved Rx 2007,NDA022074,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022074,US Approved Rx 2007,NDA022074,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022074,Acromegaly,Approved
417,103577-45-3,https://drugs.ncats.io/drug/0K5C5T2QPG,US Approved Rx 2012,ANDA202176,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202176,US Approved Rx 1995,NDA020406,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020406,,
418,7439-91-0,https://drugs.ncats.io/drug/6I3K30563S,Possibly Marketed Outside US 2010,"Lancell Slimming by MICELLBio Co., Ltd",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ef3b1b6a-9976-4cc2-bdcf-c56e6798a988,Possibly Marketed Outside US 2010,"Lancell Slimming by MICELLBio Co., Ltd",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ef3b1b6a-9976-4cc2-bdcf-c56e6798a988,,
419,231277-92-2,https://drugs.ncats.io/drug/0VUA21238F,US Approved Rx 2007,NDA022059,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022059,US Approved Rx 2007,NDA022059,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022059,Breast cancer,Approved
420,210589-09-6,https://drugs.ncats.io/drug/WP58SVM6R4,US Approved Rx 2003,BLA125058,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125058,US Approved Rx 2003,BLA125058,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125058,,
421,1223403-58-4,https://drugs.ncats.io/drug/PF9462I9HX,US Approved Rx 2018,NDA210861,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210861,US Approved Rx 2018,NDA210861,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210861,Non-Hodgkin's lymphoma; Solid tumors; Central nervous system neoplasms,Phase II; Approved; Phase II
422,130209-82-4,https://drugs.ncats.io/drug/6Z5B6HVF6O,US Approved Rx 2022,NDA216472,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216472,Possibly Marketed Outside US 1995,NDA020597,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f4881ec-2984-4853-bc25-5b14c3b79da7,Ocular hypertension; Open-angle glaucoma; Open-angle glaucoma; Ocular hypertension; Open-angle glaucoma; Ocular hypertension,Approved; Approved; Approved; Approved; Approved; Approved
423,860005-21-6,https://drugs.ncats.io/drug/I6393O0922,US Approved Rx 2022,NDA216472,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216472,Possibly Marketed Outside US 1995,NDA020597,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f4881ec-2984-4853-bc25-5b14c3b79da7,Ocular hypertension; Open-angle glaucoma; Open-angle glaucoma; Ocular hypertension; Open-angle glaucoma; Ocular hypertension,Approved; Approved; Approved; Approved; Approved; Approved
424,143-07-7,https://drugs.ncats.io/drug/1160N9NU9U,Possibly Marketed Outside US ,"Vitafol Plus by Everett Laboratories, Inc.",https://www.drugbank.ca/drugs/DB03017,Possibly Marketed Outside US 2010,21 CFR 333A,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7cf1bfa5-65fb-4aac-8454-11d3e008ec1e,Acne vulgaris; SUNBURN,Preclinical; Approved
425,156028-14-7,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
426,1510-16-3,https://drugs.ncats.io/drug/YGB5540EYF,,,,,,,,
427,151-21-3,https://drugs.ncats.io/drug/368GB5141J,Possibly Marketed Outside US ,part356,https://www.drugbank.ca/drugs/DB00815,Possibly Marketed Outside US 1952,NDA007936,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6a621a9c-7380-4a9f-ac54-75b48fe8518e,Acne; Human papilloma virus; HIV-1 infection; Herpes simplex virus type 2 infection,Approved; Preclinical; Preclinical; Preclinical
428,8002-43-5,https://drugs.ncats.io/drug/2OYE00PC25,US Approved Rx 2023,NDA215830,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215830,US Approved Rx 2023,NDA215830,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215830,,
429,1256388-51-8,https://drugs.ncats.io/drug/013TE6E4WV,US Approved Rx 2014,NDA205834,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205834,US Approved Rx 2014,NDA205834,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205834,Chronic hepatitis C,Approved
430,75706-12-6,https://drugs.ncats.io/drug/G162GK9U4W,US Approved Rx 2020,ANDA209677,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209677,US Approved Rx 1998,NDA020905,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020905,Multiple sclerosis; Active rheumatoid arthritis,Approved; Approved
431,191732-72-6,https://drugs.ncats.io/drug/F0P408N6V4,US Approved Rx 2021,ANDA201452,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201452,US Approved Rx 2005,NDA021880,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021880,Multiple myeloma; Mantle cell lymphoma; Myelodysplastic syndromes,Approved; Approved; Approved
432,129260-79-3,https://drugs.ncats.io/drug/Z8CBU6KR16,Possibly Marketed Outside US ,WHO-ATC:S01BA14,https://ginas.ncats.nih.gov/ginas/app/substance/Z8CBU6KR16,,,,Allergic conjunctivitis; Acne rosacea; Herpes zoster keratitis,Approved; Approved; Approved
433,75330-75-5,https://drugs.ncats.io/drug/9LHU78OQFD,US Approved Rx 2001,ANDA075551,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=075551,US Previously Marketed 1987,MEVACOR by MERCK,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019643,Hyperlipidemia; Coronary heart disease; Prostate cancer; Atherosclerotic cardiovascular disease; Hypercholesterolemia,Approved; Approved; Phase II; Approved; Approved
434,1977-10-2,https://drugs.ncats.io/drug/LER583670J,US Approved Rx 1988,ANDA072206,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=072206,US Previously Marketed 1975,LOXITANE by TEVA BRANDED PHARM,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017525,Schizophrenia; Schizophrenia; Bipolar I disorder,Approved; Approved; Approved
435,333963-40-9,https://drugs.ncats.io/drug/7662KG2R6K,US Approved Rx 2022,ANDA209920,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209920,US Approved Rx 2006,NDA021908,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021908,Constipation,Approved
436,9067-32-7,https://drugs.ncats.io/drug/YSE9PPT4TH,Possibly Marketed Outside US ,"Elcosys by DS TECH CO., LTD",https://www.drugbank.ca/drugs/DB08818,Possibly Marketed Outside US 2002,ANDA076559,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a75e2bb2-f89a-53f4-e053-2a95a90a93c7,Pain in osteoarthritis,Approved
437,825600-90-6,https://drugs.ncats.io/drug/5BSH2G9BH8,US Previously Marketed 2012,SURFAXIN by LEES PHARM HK,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021746,US Previously Marketed 2012,SURFAXIN by LEES PHARM HK,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021746,,
438,187164-19-8,https://drugs.ncats.io/drug/RE91AN4S8G,US Approved Rx 2013,NDA204153,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204153,US Approved Rx 2013,NDA204153,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204153,Tinea cruris; Onychomycosis; Tinea corporis; Tinea pedis,Approved; Phase II; Approved; Approved
439,936727-05-8,https://drugs.ncats.io/drug/EGP8L81APK,US Approved Rx 2018,NDA211358,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211358,US Approved Rx 2015,NDA206038,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206038,Cystic fibrosis (CF) in patients homozygous for the F508del mutation in the CFTR gene,Approved
440,82186-77-4,https://drugs.ncats.io/drug/F38R0JR742,US Approved Rx 2009,NDA022268,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022268,US Approved Rx 2009,NDA022268,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022268,Malaria,Approved
441,367514-87-2,https://drugs.ncats.io/drug/22IC88528T,US Approved Rx 2019,ANDA208049,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208049,US Approved Rx 2010,NDA200603,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=200603,Autism; Bipolar depression; Schizophrenia; Major depressive disorder,Phase III; Approved; Approved; Phase III
442,1110766-97-6,https://drugs.ncats.io/drug/6LL5JFU42F,US Approved Rx 2018,NDA210923,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210923,US Approved Rx 2018,NDA210923,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210923,Chronic liver disease,Approved
443,9034-40-6,https://drugs.ncats.io/drug/9O7312W37G,US Previously Marketed 1982,FACTREL by HIKMA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018123,Possibly Marketed Outside US 1978,NADA098379,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cddeff5b-ba19-4d92-8f91-8a6238f89c98,Hypogonadism; Amenorrhea,Approved; Approved
444,56973-41-2,https://drugs.ncats.io/drug/9YU877VU8K,,,,,,,,
445,60-40-2,https://drugs.ncats.io/drug/6EE945D3OK,US Approved Rx 2013,ANDA204054,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204054,US Previously Marketed 1956,INVERSINE by TARGACEPT,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=010251,Hypertension; Alcohol addiction,Approved; Phase III
446,68562-41-4,https://drugs.ncats.io/drug/7GR9I2683O,US Approved Rx 2005,BLA021839,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021839,US Approved Rx 2005,BLA021839,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021839,,
447,478166-15-3,https://drugs.ncats.io/drug/NZ8M50KKRG,US Previously Marketed 2005,IPLEX by INSMED,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021884,US Previously Marketed 2005,IPLEX by INSMED,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021884,,
448,644-62-2,https://drugs.ncats.io/drug/48I5LU4ZWD,US Approved Rx 1986,ANDA071081,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=071081,US Previously Marketed 1980,MECLOMEN by PARKE DAVIS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018006,Idiopathic heavy menstrual blood loss; Juvenile arthritis; Primary dysmenorrhea; Rheumatoid arthritis; Osteoarthritis,Approved; Approved; Approved; Approved; Approved
449,569-65-3,https://drugs.ncats.io/drug/3L5TQ84570,US Approved OTC ,21 CFR 336.10(d) antiemetic meclizine hydrochloride,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec336-10.xml,US Previously Marketed 1954,Bonine by Pfizer,OB NME Appendix 1950-1985,Vertigo; Motion sickness,Approved; Approved
450,13422-55-4,https://drugs.ncats.io/drug/BR1SN1JS2W,Possibly Marketed Outside US ,"Vita-Rx Diabetic Vitamin by Pure Source, Llc",https://www.drugbank.ca/drugs/DB03614,Possibly Marketed Outside US 2013,"healthy mamaBE WELL ROUNDED BE WELL ROUNDED by MATERNAL SCIENCE, LLC",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b0addefd-148c-423b-bcff-332c255a2d90,Peripheral neuropathy; Diabetic peripheral neuropathy; Vitamin B12 deficiency; Alzheimer's dementia,Phase IV; Phase IV; Not Provided; Approved
451,3380-34-5,https://drugs.ncats.io/drug/4NM5039Y5X,US Previously Marketed 1997,COLGATE TOTAL by COLGATE PALMOLIVE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020231,US Previously Marketed 1969,P-300 Antibacterial by Colgate-Palmolive,OB NME Appendix 1950-1993,Bacterial infections,Approved
452,7704-34-9,https://drugs.ncats.io/drug/a781d1f2,,,,,,,,
453,520-85-4,https://drugs.ncats.io/drug/HSU1C9YRES,US Approved Rx 2022,ANDA212844,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212844,Possibly Marketed Outside US 1959,NDA011839,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2627eb11-06bf-4a45-9172-094468e3ca07,Secondary amenorrhea; Abnormal uterine bleeding; Endometrial cancer,Approved; Approved; Approved
454,2668-66-8,https://drugs.ncats.io/drug/D2UFC189XF,US Previously Marketed 1969,HMS by ALLERGAN,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016624,US Previously Marketed 1969,HMS by ALLERGAN,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016624,Vernal conjunctivitis; Episcleritis; Allergic conjunctivitis,Approved; Approved; Approved
455,61-68-7,https://drugs.ncats.io/drug/367589PJ2C,US Approved Rx 2010,ANDA090562,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=090562,US Approved Rx 1967,NDA015034,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=015034,Pain; Primary dysmenorrhea,Approved; Approved
456,51742-87-1,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
457,3562-63-8,https://drugs.ncats.io/drug/EA6LD1M70M,US Approved Rx 1988,ANDA072422,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=072422,US Previously Marketed 1971,MEGACE by BRISTOL MYERS SQUIBB,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016979,Anorexia; Cachexia,Approved; Approved
458,131-49-7,https://drugs.ncats.io/drug/3X9MR4N98U,US Approved Rx 2022,ANDA214201,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214201,US Previously Marketed 1954,HYPAQUE by GE HEALTHCARE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=009561,Urinary system disease; Gastrointestinal disorders,Approved; Approved
459,73-31-4,https://drugs.ncats.io/drug/JL5DK93RCL,US Previously Marketed 1961,TRIPLE HORMONE MELATONIN by TAYLOR DRUG,https://books.google.com/books?id=5HC9y4UuGLwC&newbks=1&newbks_redir=0&dq=triple%20hormone%208-808&pg=PA3147#v=onepage&q=triple%20hormone%208-808&f=false,US Previously Marketed 1921,melatonin,https://catalog.hathitrust.org/Record/100163146,Jet lag syndrome; Insomnia,Not Provided; Phase III
460,977051-08-3,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
461,71125-38-7,https://drugs.ncats.io/drug/VG2QF83CGL,US Approved Rx 2021,NDA211988,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211988,US Previously Marketed 2000,MOBIC by BOEHRINGER INGELHEIM,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020938,Juvenile rheumatoid arthritis; Rheumatoid arthritis; Osteoarthritis,Approved; Approved; Approved
462,148-82-3,https://drugs.ncats.io/drug/Q41OR9510P,US Approved Rx 2020,ANDA209197,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209197,US Previously Marketed 1964,ALKERAN by APOTEX,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=014691,Epithelial carcinoma of the ovary; Multiple myeloma,Approved; Approved
463,19982-08-2,https://drugs.ncats.io/drug/W8O17SJF3T,US Approved Rx 2020,ANDA210319,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210319,US Approved Rx 2003,NDA021487,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021487,Moderate to severe dementia of the Alzheimer’s type,Approved
464,58-27-5,https://drugs.ncats.io/drug/723JX6CXY5,US Previously Marketed 1940,Kayquinone by Abbott,DeHaen 1940-1975 NMEs,US Previously Marketed 1940,Kayquinone by Abbott,DeHaen 1940-1975 NMEs,Vitamin K deficiency; Severe hypoprothrombinaemia; Allergic rhinitis,Approved; Approved; Approved
465,2124-57-4,https://drugs.ncats.io/drug/8427BML8NY,Possibly Marketed Outside US 2018,algeaSAN pro by sanPharma GmbH,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bc1e5766-fdf1-475b-8e4b-f10d73f93533,Possibly Marketed Outside US 2018,algeaSAN pro by sanPharma GmbH,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bc1e5766-fdf1-475b-8e4b-f10d73f93533,,
466,84082-70-2,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
467,1490-04-6,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
468,83-89-6,https://drugs.ncats.io/drug/H0C805XYDE,US Previously Marketed 1938,Plasmoquine E,https://books.google.com/books?id=jglFsz5EJR8C&lpg=PA381&ots=DG2kaw3Z_a&dq=AMINACRINE%20first%20marketed&pg=PA381#v=onepage&q=AMINACRINE%20first%20marketed&f=false,US Previously Marketed 1938,Plasmoquine E,https://books.google.com/books?id=jglFsz5EJR8C&lpg=PA381&ots=DG2kaw3Z_a&dq=AMINACRINE%20first%20marketed&pg=PA381#v=onepage&q=AMINACRINE%20first%20marketed&f=false,,
469,25990-43-6,https://drugs.ncats.io/drug/ONW3LB39P7,US Previously Marketed 1956,CANTIL by SANOFI AVENTIS US,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=010679,US Previously Marketed 1956,CANTIL by SANOFI AVENTIS US,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=010679,Peptic ulcer,Approved
470,59-47-2,https://drugs.ncats.io/drug/7B8PIR2954,US Previously Marketed 1961,TOLSEROL by SQUIBB,https://www.govinfo.gov/content/pkg/FR-1970-06-25/pdf/FR-1970-06-25.pdf,US Previously Marketed 1948,Tolserol by Squibb,DeHaen 1940-1975 NMEs,Painful muscular contractions,Approved
471,100-92-5,https://drugs.ncats.io/drug/TEZ91L71V4,US Previously Marketed 1947,Wyamine Sulfate by Wyeth,DeHaen 1940-1975 NMEs,US Previously Marketed 1947,Wyamine Sulfate by Wyeth,DeHaen 1940-1975 NMEs,Hypotension,Approved
472,50-12-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
473,96-88-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
474,196078-29-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
475,57-53-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
476,91-84-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
477,150-76-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
478,15015-80-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
479,235114-32-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
480,22916-47-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
481,59467-70-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
482,42794-76-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
483,120685-11-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
484,84371-65-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
485,72432-03-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
486,72599-27-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
487,64-17-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
488,96847-55-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
489,78415-72-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
490,58066-85-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
491,10118-90-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
492,38304-91-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
493,223673-61-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
494,85650-52-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
495,59122-46-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
496,50-07-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
497,53-19-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
498,65271-80-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
499,106861-44-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
500,68693-11-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
501,97-78-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
502,525-79-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
503,51022-71-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
504,42924-53-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
505,53-84-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
506,220045-89-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
507,76932-56-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
508,147-52-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
509,65472-88-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
510,20594-83-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
511,916072-89-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
512,389-08-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
513,55096-26-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
514,854601-70-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
515,465-65-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
516,16590-41-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
517,434-22-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
518,835-31-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
519,22204-53-1,https://drugs.ncats.io/drug/57Y76R9ATQ,US Approved Rx 2018,ANDA090872,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=090872,US Approved Rx 1976,NDA017581,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017581,Ankylosing spondylitis; Rheumatoid arthritis; Osteoarthritis; Tendonitis; Bursitis,Approved; Approved; Approved; Approved; Approved
520,121679-13-8,https://drugs.ncats.io/drug/QX3KXL1ZA2,US Approved Rx 2011,ANDA091552,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=091552,US Previously Marketed 1998,AMERGE by GLAXOSMITHKLINE LLC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020763,,
521,50-02-2,https://drugs.ncats.io/drug/7S5I7G3JQL,US Approved Rx 2020,ANDA210966,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210966,US Previously Marketed 1958,DECADRON by MERCK,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011664,Cyclitis; Iritis; Herpes zoster keratitis; Allergic conjunctivitis; Acne rosacea; Superficial punctate keratitis; Corneal injury; Bacterial conjunctivitis; Multiple myeloma,Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved
522,189261-10-7,https://drugs.ncats.io/drug/3JB47N2Q2P,US Approved Rx 2004,BLA125104,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125104,US Approved Rx 2004,BLA125104,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125104,,
523,7681-93-8,https://drugs.ncats.io/drug/8O0C852CPO,US Approved Rx 1978,NDA050514,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050514,US Approved Rx 1978,NDA050514,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050514,Fusarium solani keratitis; Conjunctivitis; Fungal blepharitis,Approved; Approved; Approved
524,105816-04-4,https://drugs.ncats.io/drug/41X3PWK4O2,US Approved Rx 2018,ANDA205544,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205544,Possibly Marketed Outside US 2000,NDA021204,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5cbda9bc-3c0d-4d75-a37a-994844680c8c,Type 2 diabetes mellitus,Approved
525,99200-09-6,https://drugs.ncats.io/drug/030Y90569U,US Approved Rx 2024,ANDA209741,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209741,US Approved Rx 2007,NDA021742,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021742,Hypertension; Hypertension,Approved; Approved
526,906805-06-9,https://drugs.ncats.io/drug/2BT4C47RUI,US Approved Rx 2015,BLA125547,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125547,US Approved Rx 2015,BLA125547,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125547,,
527,69049-73-6,https://drugs.ncats.io/drug/0B535E0BN0,US Previously Marketed 1992,TILADE by KING PHARMS LLC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019660,US Previously Marketed 1992,TILADE by KING PHARMS LLC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019660,,
528,83366-66-9,https://drugs.ncats.io/drug/59H4FCV1TF,US Approved Rx 2003,ANDA076037,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=076037,US Previously Marketed 1994,SERZONE by BRISTOL MYERS SQUIBB,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020152,Depression,Approved
529,763113-22-0,https://drugs.ncats.io/drug/WOH1JD9AR8,US Approved Rx 2017,NDA208558,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,US Previously Marketed 2014,LYNPARZA by ASTRAZENECA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206162,Ovarian cancer,Approved
530,1024603-93-7,https://drugs.ncats.io/drug/TT6HN20MVF,US Approved Rx 2016,BLA761038,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761038,US Approved Rx 2016,BLA761038,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761038,,
531,112-80-1,https://drugs.ncats.io/drug/2UMI9U37CP,US Previously Marketed 1921,Oleic Acid U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,US Previously Marketed 1921,Oleic Acid U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Obesity; Colorectal cancer; Type 2 diabetes mellitus; Atherosclerosis; Unknown,Phase I; Phase II; Phase I; Phase I
532,143-28-2,https://drugs.ncats.io/drug/172F2WN8DV,Possibly Marketed Outside US 2018,NADA141481,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5ff9fdb7-554f-4f91-8cfc-6d05094384c6,Possibly Marketed Outside US 1996,NDA020538,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e6f2e7ed-41a9-4a53-ac80-0cb1fa2edcbf,,
533,144689-63-4,https://drugs.ncats.io/drug/6M97XTV3HD,US Approved Rx 2010,NDA200175,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=200175,US Approved Rx 2002,NDA021286,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021286,Hypertension,Approved
534,868049-49-4,https://drugs.ncats.io/drug/VD2YSN1AFD,US Approved Rx 2014,NDA203108,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203108,US Approved Rx 2014,NDA203108,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203108,Chronic obstructive pulmonary disease,Approved
535,113806-05-6,https://drugs.ncats.io/drug/D27V6190PM,US Approved Rx 2015,ANDA206306,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206306,US Approved Rx 1996,NDA020688,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020688,Allergic conjunctivitis; Seasonal allergic rhinitis,Approved; Approved
536,15722-48-2,https://drugs.ncats.io/drug/ULS5I8J03O,US Approved Rx 1990,NDA019715,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019715,US Approved Rx 1990,NDA019715,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019715,Ulcerative colitis; Ankylosing spondylitis,Approved; Phase II
537,26833-87-4,https://drugs.ncats.io/drug/6FG8041S5B,US Approved Rx 2012,NDA203585,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203585,US Approved Rx 2012,NDA203585,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203585,"Unknown; Chronic myeloid leukemia, accelerated phase; Chronic myeloid leukemia, chronic phase",Approved; Approved
538,389139-89-3,https://drugs.ncats.io/drug/090IP5RV8F,US Approved Rx 2018,NDA209817,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209817,US Approved Rx 2018,NDA209817,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209817,Acute bacterial skin and skin structure infections; Community-acquired bacterial pneumonia; Acute Pyelonephritis; Cystitis,Approved; Approved; Phase II; Phase II
539,242138-07-4,https://drugs.ncats.io/drug/2P471X1Z11,US Approved Rx 2003,BLA103976,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103976,US Approved Rx 2003,BLA103976,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103976,,
540,1258226-87-7,https://drugs.ncats.io/drug/2302768XJ8,US Previously Marketed 2015,TECHNIVIE by ABBVIE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207931,US Previously Marketed 2015,TECHNIVIE by ABBVIE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207931,Genotype 1 chronic hepatitis C virus (HCV) infection; Genotype 4 chronic hepatitis C virus (HCV) infection without cirrhosis,Approved; Approved
541,84494-70-2,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
542,73590-58-6,https://drugs.ncats.io/drug/KG60484QX9,US Approved Rx 2018,ANDA203290,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203290,US Previously Marketed 1989,PRILOSEC by ASTRAZENECA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019810,Duodenal ulcer; Gastric ulcer; Gastroesophageal reflux disease; Pathological hypersecretory conditions,Approved; Approved; Approved; Approved
543,99614-02-5,https://drugs.ncats.io/drug/4AF302ESOS,US Approved Rx 2007,ANDA078776,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=078776,US Previously Marketed 1991,ZOFRAN by SANDOZ,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020007,Postoperative nausea and vomiting; Nausea; Vomiting,Approved; Approved; Approved
544,8008-60-4,https://drugs.ncats.io/drug/37M3MZ001L,US Previously Marketed 1921,Opium U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,US Previously Marketed 1921,Opium U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,,
545,137598-97-1,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
546,586-06-1,https://drugs.ncats.io/drug/53QOG569E0,US Approved Rx 1992,ANDA073632,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=073632,US Previously Marketed 1973,ALUPENT by BOEHRINGER INGELHEIM,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016402,Bronchial asthma,Approved
547,171099-57-3,https://drugs.ncats.io/drug/PUG62FRZ2E,US Approved Rx 2021,NDA214155,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214155,US Approved Rx 2014,NDA206334,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206334,Acute bacterial skin and skin structure infection,Approved
548,96829-58-2,https://drugs.ncats.io/drug/95M8R751W8,US Approved Rx 2007,NDA021887,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021887,US Approved Rx 1999,NDA020766,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020766,Obesity,Approved
549,16773-42-5,https://drugs.ncats.io/drug/62XCK0G93T,Possibly Marketed Outside US ,WHO-ATC:G01AF06,https://ginas.ncats.nih.gov/ginas/app/substance/62XCK0G93T,,,,Crohn's disease; Anaerobic bacterial infections; Giardiasis,Phase II; Approved; Approved
550,83-98-7,https://drugs.ncats.io/drug/AL805O9OG9,US Approved Rx 2003,ANDA040463,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=040463,US Previously Marketed 1957,DISIPAL by 3M,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=010653,,
551,9032-53-5,https://drugs.ncats.io/drug/44AIH82TSC,US Previously Marketed 1946,Hemo-Pak by Johnson & Johnson,DeHaen 1940-1975 NMEs,US Previously Marketed 1946,Hemo-Pak by Johnson & Johnson,DeHaen 1940-1975 NMEs,,
552,27025-41-8,https://drugs.ncats.io/drug/ULW86O013H,US Approved Rx 1981,NDA018469,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018469,US Approved Rx 1981,NDA018469,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018469,Dry eye syndrome,Approved
553,4350-09-8,https://drugs.ncats.io/drug/C1LJO185Q9,,,,,,,Migraine; Post-anoxic myoclonus; Major depressive disorder,Approved; Approved; Approved
554,131-57-7,https://drugs.ncats.io/drug/95OOS7VE0Y,US Previously Marketed 1992,SHADE UVAGUARD by BAYER HEALTHCARE LLC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020045,US Previously Marketed 1966,Solhar by Person-Covey,OB NME Appendix 1950-1985,Sunburns,Approved
555,99-43-4,https://drugs.ncats.io/drug/AXQ0JYM303,,,,,,,,
556,5633-20-5,https://drugs.ncats.io/drug/K9P6MC7092,US Approved Rx 2020,ANDA214415,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214415,US Previously Marketed 1975,DITROPAN by JANSSEN PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017577,Overactive bladder,Approved
557,8031-14-9,https://drugs.ncats.io/drug/3214M86B2N,US Previously Marketed 1955,Kasdenol by Kasdenol,OB NME Appendix 1950-1993,US Previously Marketed 1921,Chlorinated Lime U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,,
558,76-42-6,https://drugs.ncats.io/drug/CD35PMG570,US Approved Rx 2017,ANDA207418,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207418,US Approved Rx 1950,NDA007337,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=007337,Osteoarthritis; Opioid-related disorders; Acute and chronic pain,Phase III; Phase II; Approved
559,1491-59-4,https://drugs.ncats.io/drug/8VLN5B44ZY,US Approved OTC ,21 CFR 341.20(b)(7) cough/cold:nasal decongestant oxymetazoline hydrochloride,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec341-20.xml,US Previously Marketed 1964,Afrin by Schering,OB NME Appendix 1950-1985,Nasal congestion; Eye irritations,Approved; Approved
560,434-07-1,https://drugs.ncats.io/drug/L76T0ZCA8K,US Previously Marketed 1960,Adroyd by Parke-Davis,DeHaen 1940-1975 NMEs,US Previously Marketed 1960,Adroyd by Parke-Davis,DeHaen 1940-1975 NMEs,Anemia,Approved
561,76-41-5,https://drugs.ncats.io/drug/9VXA968E0C,US Approved Rx 2014,ANDA201187,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201187,US Previously Marketed 1959,OPANA by ENDO PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011707,Pain; Anxiety,Approved; Approved
562,79-57-2,https://drugs.ncats.io/drug/SLF0D9077S,US Approved OTC ,21 CFR 333.120 first aid antibiotic:ointment oxytetracycline hydrochloride (combination only),https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec333-120.xml,US Previously Marketed 1950,Terramycin HCl by Pfizer,DeHaen 1940-1975 NMEs,Superficial ocular infections,Approved
563,50-56-6,https://drugs.ncats.io/drug/1JQS135EYN,US Approved Rx 2018,ANDA091676,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=091676,US Previously Marketed 1928,Pitocin,https://books.google.com/books?id=AymgAAAAMAAJ&lpg=PA514&ots=Sv2C9092O9&dq=pitocin%201928&pg=PA514#v=onepage&q=pitocin%201928&f=false,Uterine hemorrhage; Labor,Approved; Approved
564,150-13-0,https://drugs.ncats.io/drug/TL2TJE8QTX,US Previously Marketed 1961,PABIRIN AC AMINOBENZOIC ACID by DORSEY,https://cdn.loc.gov/service/ll/fedreg/fr035/fr035061/fr035061.pdf,Possibly Marketed Outside US 1943,NDA005378,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f03a68d5-ed00-8a2d-af68-28be909ea85f,Rheumatoid arthritis; Eczema dermatitis; Dermatoses; Atopic dermatitis,Not Provided; Not Provided; Not Provided; Not Provided
565,100-09-4,https://drugs.ncats.io/drug/4SB6Y7DMM3,Possibly Marketed Outside US 2016,M016,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a29fb680-cfc8-4a7b-9970-563fa0e2bed6,Possibly Marketed Outside US 1996,21 CFR 352,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14c78e8a-eb3e-496b-9cb0-7f8b47b3fb2a,,
566,99-96-7,https://drugs.ncats.io/drug/JG8Z55Y12H,Possibly Marketed Outside US 2015,21 CFR 352,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c16e8c37-6773-4fc9-9ea8-bda005742988,Possibly Marketed Outside US 2015,21 CFR 352,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c16e8c37-6773-4fc9-9ea8-bda005742988,,
567,18979-53-8,https://drugs.ncats.io/drug/UHM852UB1I,,,,,,,,
568,98-67-9,https://drugs.ncats.io/drug/L74LRO149A,Possibly Marketed Outside US ,DEBACTEROL Canker Sore Pain Relief by Epien Medical Inc,https://www.drugbank.ca/drugs/DB14739,Possibly Marketed Outside US 1996,DEBACTEROL Canker Sore Pain Relief by EPIEN Medical Inc,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=15d22ca4-503e-2751-e054-00144ff8d46c,Unknown; Unknown; Aphthous ulcers,Approved
569,33069-62-4,https://drugs.ncats.io/drug/P88XT4IS4D,US Approved Rx 2018,ANDA205720,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205720,US Previously Marketed 1992,TAXOL by HQ SPCLT PHARMA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020262,Advanced carcinoma of the ovary; Non-small cell lung cancer; Breast cancer,Approved; Approved; Approved
570,21245-02-3,https://drugs.ncats.io/drug/Z11006CMUZ,US Previously Marketed 1988,Photoplex by Herbert,OB NME Appendix 1950-1993,Possibly Marketed Outside US 1964,21 CFR 358A,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0cc6cd4-8dea-4615-b763-2733f1582a66,Photosensitivity disorders,Approved
571,571190-30-2,https://drugs.ncats.io/drug/G9ZF61LE7G,US Approved Rx 2015,NDA207103,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207103,US Approved Rx 2015,NDA207103,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207103,"Estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer",Approved
572,162394-19-6,https://drugs.ncats.io/drug/QMS40680K6,US Approved Rx 2004,BLA125103,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125103,US Approved Rx 2004,BLA125103,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125103,,
573,144598-75-4,https://drugs.ncats.io/drug/838F01T721,US Approved Rx 2015,ANDA203802,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203802,US Approved Rx 2006,NDA021999,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021999,Schizophrenia,Approved
574,199739-10-1,https://drugs.ncats.io/drug/R8P8USM8FR,US Approved Rx 2015,ANDA203802,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203802,US Approved Rx 2006,NDA021999,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021999,Schizophrenia,Approved
575,188039-54-5,https://drugs.ncats.io/drug/DQ448MW7KS,US Approved Rx 1998,BLA103770,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103770,US Approved Rx 1998,BLA103770,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103770,,
576,52645-53-1,https://drugs.ncats.io/drug/509F88P9SZ,US Approved Rx 1989,NDA019855,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019855,US Previously Marketed 1986,NIX by GLAXOSMITHKLINE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019435,Head lice infestation; Scabies; Pediculosis; Scabies,Approved; Approved; Approved; Approved
577,726169-73-9,https://drugs.ncats.io/drug/A6GWB8T96J,Clinical ,INN:mocetinostat [INN],https://ginas.ncats.nih.gov/ginas/app/substance/A6GWB8T96J,,,,Chronic lymphocytic leukemia; Myelodysplastic syndromes; Non-small cell lung cancer,Phase II; Phase II; Phase II
578,58-39-9,https://drugs.ncats.io/drug/FTA7XXY4EZ,US Approved Rx 2022,ANDA210163,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210163,US Previously Marketed 1957,TRILAFON by SCHERING,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=010775,Depression; Anxiety; Nausea; Schizophrenia; Vomiting,Approved; Approved; Approved; Approved; Approved
579,380610-27-5,https://drugs.ncats.io/drug/K16AIQ8CTM,US Approved Rx 2020,BLA761170,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761170,US Approved Rx 2012,BLA125409,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125409,,
580,8007-00-9,https://drugs.ncats.io/drug/8P5F881OCY,US Approved Allergenic Extract 1994,BLA103738,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f082b68-dc74-418a-9e6f-b3c285b41d44,US Previously Marketed 1921,Balsam of Peru U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,,
581,57-42-1,https://drugs.ncats.io/drug/9E338QE28F,US Approved Rx 1942,NDA021171,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021171,US Previously Marketed 1942,DEMEROL by VALIDUS PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=005010,Pain,Approved
582,60-80-0,https://drugs.ncats.io/drug/T3CHA1B51H,US Previously Marketed 1885,Antipyrine,https://books.google.com/books?id=Cb6BOkj9fK4C&lpg=PA126&ots=NPafI1BddW&dq=phenazone%20%20discovery&pg=PA126#v=onepage&q=phenazone%20%20discovery&f=false,US Previously Marketed 1885,Antipyrine,https://books.google.com/books?id=Cb6BOkj9fK4C&lpg=PA126&ots=NPafI1BddW&dq=phenazone%20%20discovery&pg=PA126#v=onepage&q=phenazone%20%20discovery&f=false,Otitis media; Asthma; Pain,Approved; Phase II; Not Provided
583,94-78-0,https://drugs.ncats.io/drug/K2J09EMJ52,US Previously Marketed 2001,SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PHENAZOPYRIDINE HYDROCHLORIDE by ABLE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021105,US Previously Marketed 1928,Pyridium,https://www.ncbi.nlm.nih.gov/pubmed/982458,Urinary tract infections; Urinary tract infections,Approved; Approved
584,634-03-7,https://drugs.ncats.io/drug/AB2794W8KV,US Approved Rx 2010,ANDA091042,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=091042,US Previously Marketed 1961,Plegine by Ayerst,OB NME Appendix 1950-1985,Exogenous obesity,Approved
585,51-71-8,https://drugs.ncats.io/drug/O408N561GF,US Approved Rx 1961,NDA011909,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011909,US Approved Rx 1961,NDA011909,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011909,Depression,Approved
586,64-04-0,https://drugs.ncats.io/drug/327C7L2BXQ,,,,,,,Depression,Natural Metabolite
587,82-88-2,https://drugs.ncats.io/drug/772BQ8KSST,US Approved OTC ,21 CFR 341.12(i) cough/cold:antihistamine phenindamine tartrate,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec341-12.xml,US Previously Marketed 1947,Thephorin by Hoffmann-La Roche,DeHaen 1940-1975 NMEs,Allergy,Approved
588,86-21-5,https://drugs.ncats.io/drug/134FM9ZZ6M,US Approved OTC ,21 CFR 341.12(j) cough/cold:antihistamine pheniramine maleate,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec341-12.xml,US Previously Marketed 1948,Trimeton by Schering,DeHaen 1940-1975 NMEs,Allergic conditions; Neurodermatitis; Eye diseases; Meniere's disease; Motion sickness,Approved; Approved; Approved; Approved; Approved
589,50-06-6,https://drugs.ncats.io/drug/YQE403BP4D,US Approved Rx 2022,NDA215910,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215910,US Previously Marketed 1912,Luminal,https://archive.org/details/newnonofficialre39coun,Anxiety; Insomnia; Tonic-clonic seizures; Febrile seizures; Epilepsy; Hyperbilirubinemia; Cholestasis; Status epilepticus,Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved
590,108-95-2,https://drugs.ncats.io/drug/339NCG44TV,US Approved Allergenic Extract 1941,BLA103888,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d756bf9e-2e57-48a4-897a-ec1d96472dec,US Previously Marketed 1921,Phenol U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Unknown; Sore throat; Onychocryptosis,Approved; Approved
591,77-09-8,https://drugs.ncats.io/drug/6QK969R2IF,US Previously Marketed 1921,Phenolphthalein U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,US Previously Marketed 1921,Phenolphthalein U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Constipation,Approved
592,59-96-1,https://drugs.ncats.io/drug/0TTZ664R7Z,US Approved Rx 2017,ANDA204522,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204522,US Approved Rx 1953,NDA008708,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=008708,Pheochromocytoma,Approved
593,122-09-8,https://drugs.ncats.io/drug/C045TQL4WP,US Approved Rx 2008,ANDA040876,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=040876,US Previously Marketed 1959,IONAMIN by UCB INC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011613,Obesity,Approved
594,50-60-2,https://drugs.ncats.io/drug/Z468598HBV,US Approved Rx 2017,ANDA207686,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207686,US Previously Marketed 1952,Regitine HCl by Ciba,OB NME Appendix 1950-1985,,
595,63-91-2,https://drugs.ncats.io/drug/47E5O17Y3R,US Previously Marketed ,21 CFR 310.545(a)(20) weight control phenylalanine,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec310-545.xml,Possibly Marketed Outside US 1971,NDA016822,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa89dad1-bf4f-4f7e-ad1b-2431bdf36a2d,Pain; Depression; Burns,Not Provided; Not Provided; Approved
596,1821-12-1,https://drugs.ncats.io/drug/7WY7YBI87E,US Approved Rx 2022,ANDA216462,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216462,US Approved Rx 1996,NDA020573,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020573,Late-onset disease; Urea cycle disorders,Approved; Approved
597,59-42-7,https://drugs.ncats.io/drug/1WS297W6MV,US Approved OTC ,21 CFR 349.18(c) ophthalmic:vasoconstrictor phenylephrine hydrochloride (0.08 to 0.2%),https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec349-18.xml,US Previously Marketed 1934,Neosynephrine,https://books.google.com/books?id=kcVEAQAAMAAJ&newbks=1&newbks_redir=0&dq=phenylephrine%201934&pg=PA760#v=onepage&q=phenylephrine%201934&f=false,Hypotension; Eye diseases,Approved; Approved
598,33987-92-7,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
599,48115-38-4,https://drugs.ncats.io/drug/683H0R9659,,,,,,,,
600,92-12-6,https://drugs.ncats.io/drug/K65LB6598J,US Previously Marketed 1961,HISTIONEX 50 by STRASENBURGH,https://cdn.loc.gov/service/ll/fedreg/fr047/fr047020/fr047020.pdf,US Previously Marketed 1952,Bristamin by Bristol,DeHaen 1940-1975 NMEs,Fever; Premenstrual and menstrual cramps; Headache; Minor aches; Allergy,Not Provided; Not Provided; Not Provided; Not Provided; Approved
601,2062-78-4,https://drugs.ncats.io/drug/1HIZ4DL86F,US Approved Rx 2015,ANDA204521,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204521,US Previously Marketed 1984,ORAP by TEVA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017473,Tourette's syndrome,Approved
602,13523-86-9,https://drugs.ncats.io/drug/BJ4HF6IU1D,US Approved Rx 1992,ANDA074019,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=074019,US Previously Marketed 1982,VISKEN by NOVARTIS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018285,Hypertension; Hypertension,Approved; Approved
603,111025-46-8,https://drugs.ncats.io/drug/X4OV71U42S,US Approved Rx 2005,NDA021842,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021842,US Approved Rx 1999,NDA021073,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021073,X-linked adrenoleukodystrophy; Friedreich ataxia; Type 2 diabetes mellitus,Approved; Phase III; Approved
604,52212-02-9,https://drugs.ncats.io/drug/R6ZTY81RE1,US Previously Marketed 1990,ARDUAN by ORGANON USA INC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019638,US Previously Marketed 1990,ARDUAN by ORGANON USA INC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019638,Pain,Approved
605,61477-96-1,https://drugs.ncats.io/drug/9I628532GX,US Approved Rx 2017,ANDA207848,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207848,US Previously Marketed 1981,PIPRACIL by WYETH PHARMS INC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050545,Intra-abdominal infections; Skin and skin structure infections; Female pelvic infections; Community-acquired pneumonia; Nosocomial pneumonia,Approved; Approved; Approved; Approved; Approved
606,7280-37-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
607,51-03-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
608,7491-74-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
609,38677-81-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
610,53179-13-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
611,50650-76-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
612,36322-90-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
613,147511-69-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
614,62354-43-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
615,1154757-24-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
616,467426-54-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
617,110078-46-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
618,18378-89-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
619,518-28-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
620,9000-55-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
621,71-23-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
622,3055-99-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
623,171228-49-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
624,7440-09-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
625,7722-64-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
626,9003-39-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
627,25655-41-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
628,146464-95-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
629,6735-59-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
630,104632-26-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
631,151126-32-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
632,140-65-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
633,53-43-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
634,150322-43-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
635,60-87-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
636,54063-53-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
637,74-98-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
638,298-50-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
639,1211441-98-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
640,83-88-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
641,10257-32-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
642,141-22-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
643,72559-06-9,https://drugs.ncats.io/drug/1W306TDA6S,US Approved Rx 2019,NDA213004,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213004,US Approved Rx 1992,NDA050689,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050689,Disseminated Mycobacterium avium complex (MAC) disease,Approved
644,13292-46-1,https://drugs.ncats.io/drug/VJT6J7R4TR,US Approved Rx 2016,ANDA205039,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205039,US Previously Marketed 1971,RIFADIN by SANOFI AVENTIS US,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050420,Tuberculosis; Asymptomatic meningococcal infection,Approved; Approved
645,61379-65-5,https://drugs.ncats.io/drug/XJM390A33U,US Approved Rx 1998,NDA021024,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021024,US Approved Rx 1998,NDA021024,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021024,Pulmonary tuberculosis,Approved
646,80621-81-4,https://drugs.ncats.io/drug/L36O5T016N,US Approved Rx 2004,NDA021361,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021361,US Approved Rx 2004,NDA021361,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021361,Irritable bowel syndrome with diarrhea; Overt hepatic encephalopathy recurrence; Travelers’ diarrhea,Approved; Approved; Approved
647,501081-76-1,https://drugs.ncats.io/drug/8K80YB5GMG,US Approved Rx 2008,BLA125249,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125249,US Approved Rx 2008,BLA125249,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125249,,
648,500287-72-9,https://drugs.ncats.io/drug/FI96A8X663,US Approved Rx 2011,NDA202022,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202022,US Approved Rx 2011,NDA202022,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202022,HIV-1 infection,Approved
649,1744-22-5,https://drugs.ncats.io/drug/7LJ087RS6F,US Approved Rx 1995,NDA020599,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020599,US Approved Rx 1995,NDA020599,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020599,Amyotrophic lateral sclerosis,Approved
650,13392-28-4,https://drugs.ncats.io/drug/0T2EF4JQTU,US Approved Rx 2002,ANDA076132,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=076132,US Previously Marketed 1993,FLUMADINE by SUN PHARM INDS INC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019649,Influenza A virus infection; Respiratory tract infections,Approved; Phase II
651,49697-38-3,https://drugs.ncats.io/drug/O7M2E4264D,US Previously Marketed 1994,VEXOL by HARROW EYE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020474,US Previously Marketed 1994,VEXOL by HARROW EYE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020474,Postoperative inflammation following ocular surgery; Anterior uveitis,Approved; Approved
652,625115-55-1,https://drugs.ncats.io/drug/RU3FE2Y4XI,US Approved Rx 2022,ANDA211135,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211135,US Approved Rx 2013,NDA204819,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204819,Pulmonary arterial hypertension; Chronic thromboembolic pulmonary hypertension,Approved; Approved
653,105462-24-6,https://drugs.ncats.io/drug/KM2Z91756Z,US Approved Rx 2014,ANDA079215,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=079215,US Approved Rx 1998,NDA020835,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020835,Paget’s disease of bone; Postmenopausal osteoporosis; Glucocorticoid-induced osteoporosis; Increase bone mass in men with osteoporosis,Approved; Approved; Approved; Approved
654,106266-06-2,https://drugs.ncats.io/drug/L6UH7ZF8HC,US Approved Rx 2009,ANDA077719,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=077719,US Approved Rx 1993,NDA020272,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020272,Schizophrenia; Irritability associated with autistic disorder; Acute manic or mixed episodes associated with Bipolar I disorder,Approved; Approved; Approved
655,26652-09-5,https://drugs.ncats.io/drug/I0Q6O6740J,US Previously Marketed 1991,RITODRINE HYDROCHLORIDE by HOSPIRA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=071619,US Previously Marketed 1980,Ritodrine by Duphar,OB NME Appendix 1950-1985,Preterm labor,Approved
656,155213-67-5,https://drugs.ncats.io/drug/O3J8G9O825,US Approved Rx 2016,ANDA207407,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207407,US Previously Marketed 1996,NORVIR by ABBOTT,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020680,HIV-1 infection,Approved
657,174722-31-7,https://drugs.ncats.io/drug/4F4X42SYQ6,US Approved Rx 2017,BLA761064,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761064,US Approved Rx 1997,BLA103705,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103705,,
658,366789-02-8,https://drugs.ncats.io/drug/9NDF7JZ4M3,US Approved Rx 2011,NDA202439,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202439,US Approved Rx 2011,NDA202439,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202439,Pulmonary embolism,Approved
659,123441-03-2,https://drugs.ncats.io/drug/PKI06M3IW0,US Approved Rx 2012,ANDA091689,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=091689,US Previously Marketed 2000,EXELON by NOVARTIS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020823,Mild to moderate dementia associated with Parkinson’s disease; Alzheimer’s disease; Mild to moderate dementia of the Alzheimer’s type,Approved; Phase IV; Approved
660,144034-80-0,https://drugs.ncats.io/drug/51086HBW8G,US Approved Rx 2013,ANDA201914,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201914,US Approved Rx 1998,NDA020864,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020864,Migraine with aura; Migraine with aura,Approved; Approved
661,119302-91-9,https://drugs.ncats.io/drug/I65MW4OFHZ,US Approved Rx 2008,ANDA079195,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=079195,US Previously Marketed 1994,ZEMURON by ORGANON USA INC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020214,Pain,Approved
662,162011-90-7,https://drugs.ncats.io/drug/0QTW8Z7MCR,US Previously Marketed 1999,VIOXX by MERCK,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021052,US Previously Marketed 1999,VIOXX by MERCK,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021052,Hemophilic Arthropathy; Rheumatoid arthritis; Migraine; Osteoarthritis; Acute pain; Primary dysmenorrhea,Phase II; Withdrawn; Withdrawn; Withdrawn; Withdrawn; Withdrawn
663,162401-32-3,https://drugs.ncats.io/drug/0P6C6ZOP5U,US Approved Rx 2020,ANDA208247,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208247,US Approved Rx 2011,NDA022522,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022522,Chronic obstructive pulmonary disease,Approved
664,552292-08-7,https://drugs.ncats.io/drug/NLE429IZUC,US Approved Rx 2015,NDA206500,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206500,US Approved Rx 2015,NDA206500,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206500,Delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy,Approved
665,128517-07-7,https://drugs.ncats.io/drug/CX3T89XQBK,US Approved Rx 2021,ANDA206254,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206254,US Approved Rx 2009,NDA022393,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022393,,
666,267639-76-9,https://drugs.ncats.io/drug/GN5XU2DXKV,US Approved Rx 2008,BLA125268,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125268,US Approved Rx 2008,BLA125268,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125268,,
667,91374-21-9,https://drugs.ncats.io/drug/030PYR8953,US Approved Rx 2012,ANDA091395,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=091395,US Previously Marketed 1997,REQUIP by GLAXOSMITHKLINE LLC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020658,Restless legs syndrome; Sexual dysfunction; Parkinson's disease,Approved; Phase IV; Approved
668,84057-95-4,https://drugs.ncats.io/drug/7IO5LYA57N,US Approved Rx 2014,ANDA078601,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=078601,US Approved Rx 1996,NDA020533,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020533,Pain,Approved
669,632-99-5,https://drugs.ncats.io/drug/8UUC89LHB2,US Previously Marketed ,21 CFR 310.545(a)(22)(ii) antifungal:diaper rash basic fuchsin,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec310-545.xml,Possibly Marketed Outside US 1972,21 CFR 333A,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3aa69d68-7a22-4a55-9682-ecc14540984a,Skin infections; Unknown,Approved
670,84696-47-9,https://drugs.ncats.io/drug/1871c73f,,,,,,,,
671,11121-48-5,https://drugs.ncats.io/drug/BIU7Q7W2SH,Clinical 2015,NCT02322086: Phase 2 Interventional Completed Psoriasis,https://clinicaltrials.gov/ct2/show/NCT02322086,,,,Unknown,
672,122320-73-4,https://drugs.ncats.io/drug/05V02F2KDG,US Previously Marketed 2007,ROSIGLITAZONE by WATSON LABS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=078023,US Previously Marketed 1999,AVANDIA by WOODWARD,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021071,Type 2 diabetes mellitus,Approved
673,3650-09-7,https://drugs.ncats.io/drug/LI791SXT24,,,,,,,Ultraviolet-induced erythema,Not Provided
674,287714-41-4,https://drugs.ncats.io/drug/413KH5ZJ73,US Approved Rx 2016,ANDA079169,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=079169,US Approved Rx 2003,NDA021366,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021366,Dyslipidemia; Hypertriglyceridemia; Dysbetalipoproteinemia; Hypercholesterolemia; Atherosclerosis,Approved; Approved; Approved; Approved; Approved
675,99755-59-6,https://drugs.ncats.io/drug/87T4T8BO2E,US Approved Rx 2007,NDA021829,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021829,US Approved Rx 2007,NDA021829,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021829,Restless legs syndrome; Parkinson's disease,Approved; Approved
676,8031-67-2,https://drugs.ncats.io/drug/L497I37F0C,Possibly Marketed Outside US ,Yellow Toner by Iruri Nature Handmade Soap & Cosmetic Inc,https://www.drugbank.ca/drugs/DB14250,Possibly Marketed Outside US 2017,Yellow Toner by Iruri Nature Handmade Soap & Cosmetic Inc,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=551513bc-e3dc-618c-e054-00144ff88e88,,
677,283173-50-2,https://drugs.ncats.io/drug/8237F3U7EH,US Approved Rx 2016,NDA209115,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209115,US Approved Rx 2016,NDA209115,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209115,Castrate-resistant prostate cancer; Breast cancer; Ovarian cancer; Melanoma,Phase III; Phase II; Approved; Phase II
678,106308-44-5,https://drugs.ncats.io/drug/WFW942PR79,US Approved Rx 2016,ANDA204988,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204988,US Approved Rx 2008,NDA021911,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021911,Lennox-Gastaut syndrome,Approved
679,1417412-83-9,https://drugs.ncats.io/drug/5X3GF74R79,Possibly Marketed Outside US 2021,NCT04690322: Phase 4 Interventional Recruiting Hemophilia A,https://clinicaltrials.gov/ct2/show/NCT04690322,,,,,
680,153-18-4,https://drugs.ncats.io/drug/5G06TVY3R7,US Previously Marketed 1921,rutin,https://catalog.hathitrust.org/Record/100163146,US Previously Marketed 1921,rutin,https://catalog.hathitrust.org/Record/100163146,Osteoarthritis; Open-angle glaucoma; Postmastectomy lymphoedema of the arm,Approved; Phase II; Approved
681,941678-49-5,https://drugs.ncats.io/drug/82S8X8XX8H,US Approved Rx 2011,NDA202192,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202192,US Approved Rx 2011,NDA202192,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202192,Primary myelofibrosis; Polycythemia vera,Approved; Approved
682,81-07-2,https://drugs.ncats.io/drug/FST467XS7D,US Previously Marketed 1921,Benzosulphinide U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,US Previously Marketed 1921,Benzosulphinide U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Unknown,
683,554-62-1,https://drugs.ncats.io/drug/GIN46U9Q2Q,Possibly Marketed Outside US ,"P1P AC Repair Ampoule by Phytos Co., Ltd.",https://www.drugbank.ca/drugs/DB14119,Possibly Marketed Outside US 2002,M020,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4bfbfac7-6738-4996-a152-95dfbd759154,Metabolic syndrome; Acne vulgaris; Hyperpigmentation; Skin Care,Phase II; Phase II; Basic research; Approved
684,85897-35-4,https://drugs.ncats.io/drug/8A7F670F2Y,US Approved Rx 1998,BLA020772,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020772,US Approved Rx 1998,BLA020772,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020772,,
685,149709-62-6,https://drugs.ncats.io/drug/17ERJ0MKGI,US Approved Rx 2015,NDA207620,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207620,US Approved Rx 2015,NDA207620,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207620,Chronic heart failure,Approved
686,111-01-3,https://drugs.ncats.io/drug/GW89575KF9,,,,,,,Sunburn,Approved
687,111-02-4,https://drugs.ncats.io/drug/7QWM220FJH,Possibly Marketed Outside US 2015,BLA125510,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05be1932-bb7a-4e3a-9200-4ccdc5565edc,Possibly Marketed Outside US 2002,21 CFR 352,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=172ce1b6-4f93-4f2e-95f7-7315a5f2b6fd,Hypercholesterolemia; Obesity; Cancer; Hypertension,Phase I; Preclinical; Preclinical; Preclinical
688,2892-62-8,https://drugs.ncats.io/drug/4RTO57VG65,US Previously Marketed 2019,squaric acid dibutyl ester,https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23,US Previously Marketed 2019,squaric acid dibutyl ester,https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23,,
689,302-96-5,https://drugs.ncats.io/drug/4R1VB9P8V3,US Previously Marketed 1962,WINSTROL by LUNDBECK INC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012885,US Previously Marketed 1962,WINSTROL by LUNDBECK INC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012885,Angioedema,Approved
690,9005-25-8,https://drugs.ncats.io/drug/0d382dd7,,,,,,,,
691,3056-17-5,https://drugs.ncats.io/drug/BO9LE4QFZF,US Previously Marketed 2007,LAMIVUDINE; STAVUDINE by MATRIX LABS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022085,US Previously Marketed 1994,ZERIT by BRISTOL,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020412,HIV-1 infection,Approved
692,57-11-4,https://drugs.ncats.io/drug/4ELV7Z65AP,US Previously Marketed 1921,Stearic Acid U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,US Previously Marketed 1921,Stearic Acid U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Sunburn; Skin Diseases; Type 2 diabetes mellitus; Diabetic foot; Dyslipidemia,Approved; Approved; Phase I; Phase I; Phase I
693,123-94-4,https://drugs.ncats.io/drug/258491E1RZ,US Previously Marketed ,"21 CFR 310.545(a)(18)(i)(B) skin protectant:w/ sales less than $25,000 glyceryl stearate",https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec310-545.xml,Possibly Marketed Outside US 1971,ANDA090256,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9ff7fa78-0fca-976f-e053-2995a90a4641,Dry Skin,Approved
694,9000-36-6,https://drugs.ncats.io/drug/73W9IQY50Q,US Approved Allergenic Extract 1965,BLA103753,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=721936bc-3d1f-4be5-bb4a-9c87898aff37,US Approved Allergenic Extract 1965,BLA103753,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=721936bc-3d1f-4be5-bb4a-9c87898aff37,,
695,58543-16-1,https://drugs.ncats.io/drug/B3FUD0528F,Possibly Marketed Outside US 2018,21 CFR 334,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0effa2f8-b1ee-4963-a2aa-20832703fc4e,Possibly Marketed Outside US 2015,21 CFR 341,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6d82469b-d51c-4824-9830-6c1874ad4fe4,,
696,57817-89-7,https://drugs.ncats.io/drug/0YON5MXJ9P,Possibly Marketed Outside US 2016,21 CFR 352,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2fd24cc7-5007-1117-e054-00144ff88e88,Possibly Marketed Outside US 2013,21 CFR 355,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d6adca01-eb68-46e3-b988-654baf046a6e,Cancer; Hypertension; Dental caries,Basic research; Phase I; Phase II
697,83-48-7,https://drugs.ncats.io/drug/99WUK5D0Y8,Clinical ,Br J Nutr. Nov 2008;100(5):937-41.: Not Applicable Human clinical trial Completed  Hypercholesterolemia/metabolism,https://dx.doi.org/10.1017/s0007114508966113,,,,Unknown,
698,471-34-1,https://drugs.ncats.io/drug/H0G9379FGK,US Approved OTC ,21 CFR 331.11(i)(2) antacid:calcium-containing calcium (mono or dibasic salt),https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec331-11.xml,US Previously Marketed 1921,Precipitated Calcium Phosphate N.F.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Unknown; Hypocalcemia; Chronic obstructive pulmonary disease; Cystic fibrosis; Unknown; Hypocalcemia,Not Provided; Phase I; Phase I; Approved
699,9002-01-1,https://drugs.ncats.io/drug/8X1OXL3SNU,Possibly Marketed Outside US ,Canada:STREPTOKINASE,https://tripod.nih.gov/npc/#Download,,,,,
700,57-92-1,https://drugs.ncats.io/drug/Y45QSO73OB,US Approved Rx 1998,ANDA064210,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=064210,US Previously Marketed 1946,STREPTOMYCIN SULFATE by PFIZER,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=060076,Tularemia; Chancroid; Tuberculosis; Plague,Approved; Approved; Approved; Approved
701,4480-58-4,https://drugs.ncats.io/drug/IAB9JFQ8U2,Clinical ,INN:streptoniazid,https://tripod.nih.gov/npc/#Download,,,,,
702,18883-66-4,https://drugs.ncats.io/drug/5W494URQ81,US Approved Rx 1982,NDA050577,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050577,US Approved Rx 1982,NDA050577,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050577,Malignant neoplasms of pancreas (metastatic islet cell carcinoma),Approved
703,7440-24-6,https://drugs.ncats.io/drug/YZS2RPE8LE,Possibly Marketed Outside US 2012,21 CFR 352,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=86f0e36e-e824-483a-9a53-3b20cf109844,Possibly Marketed Outside US 2012,21 CFR 352,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=86f0e36e-e824-483a-9a53-3b20cf109844,,
704,304-55-2,https://drugs.ncats.io/drug/DX1U2629QE,US Approved Rx 1991,NDA019998,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019998,Possibly Marketed Outside US 1982,NDA214993,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ddd90c4a-5792-49c9-837f-710d1a604742,Lead poisoning in children,Approved
705,110-15-6,https://drugs.ncats.io/drug/AB6MNQ6J6L,US Previously Marketed 1921,sodium succinate,https://catalog.hathitrust.org/Record/100163146,US Previously Marketed 1921,sodium succinate,https://catalog.hathitrust.org/Record/100163146,Hypertension; Gastrointestinal infections; Overactive bladder,Approved; Not Provided; Approved
706,54182-58-0,https://drugs.ncats.io/drug/XX73205DH5,US Approved Rx 2022,ANDA215576,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215576,US Approved Rx 1981,NDA018333,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018333,Ulcer,Approved
707,56038-13-2,https://drugs.ncats.io/drug/96K6UQ3ZD4,Possibly Marketed Outside US 2008,21 CFR 334,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d96986dd-eab8-4025-9987-77deb208972e,Possibly Marketed Outside US 2006,Antiseptic Rinse by Meijer,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f6c5d4cd-6d6f-4efa-b455-3a9f3b2aab34,Glucose Metabolism Disorders; Diarrhea; Gingivitis,Approved; Approved; Approved
708,8047-67-4,https://drugs.ncats.io/drug/FZ7NYF5N8L,US Approved OTC ,21 CFR 347.10(c) skin protectant calamine,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec347-10.xml,US Previously Marketed 1921,Saccharated Ferric Oxide N.F.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Iron deficiency anemia; Radioactive cesium and/or radioactive or non-radioactive thallium internal contamination; Pain; Unknown; Chronic kidney disease; Unknown; Unknown; Unknown; Dental diseases; Parenteral Nutrition; Iron deficiency,Approved; Approved; Approved; Approved; Basic research; Approved; Approved
709,57-50-1,https://drugs.ncats.io/drug/ababee2a,,,,,,,,
710,56030-54-7,https://drugs.ncats.io/drug/AFE2YW0IIZ,US Approved Rx 2018,NDA209128,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209128,US Approved Rx 1984,NDA019050,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019050,Pain,Approved
711,343306-71-8,https://drugs.ncats.io/drug/361LPM2T56,US Approved Rx 2015,NDA022225,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022225,US Approved Rx 2015,NDA022225,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022225,Neuromuscular blockade,Approved
712,68373-14-8,https://drugs.ncats.io/drug/S4TF6I2330,US Approved Rx 2023,NDA216974,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216974,US Approved Rx 1986,NDA050608,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050608,Staphylococcus aureus (beta-lactamase and non-beta-lactamase producing); Staphylococcus epidermidis (beta-lactamase and non-beta-lactamase producing); Moraxella (Branhamella) catarrhalis (beta-lactamase and non-beta-lactamase producing); Bacterial infections; Peptostreptococcus species; Hemophilus influenzae  (beta-lactamase and non-beta-lactamase producing),Approved; Approved; Approved; Approved; Approved; Approved
713,61318-90-9,https://drugs.ncats.io/drug/5D9HAA5Q5S,US Approved Rx 1985,NDA018738,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018738,US Approved Rx 1985,NDA018738,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018738,Tinea Corporis; Tinea cruris; Athlete’s foot,Approved; Approved; Approved
714,127-71-9,https://drugs.ncats.io/drug/G58F8OPL4I,US Previously Marketed 1985,TRIPLE SULFA by PHARMADERM,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=088462,US Previously Marketed 1945,SULTRIN by ORTHO MCNEIL PHARM,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=005794,Vaginitis caused by Gardnerella vaginalis,Approved
715,144-80-9,https://drugs.ncats.io/drug/4965G3J0F5,US Approved Rx 1994,ANDA040066,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=040066,US Previously Marketed 1941,Sulamyd by Schering,DeHaen 1940-1975 NMEs,Eye infections; Acne vulgaris,Approved; Approved
716,68-35-9,https://drugs.ncats.io/drug/0N7609K889,US Approved Rx 1994,ANDA040091,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=040091,US Previously Marketed 1941,Sulfadiazine Sodium by DeHaen 1940-1975 NMEs,*!,Toxoplasmosis encephalitis; Urinary tract infections; Malaria,Approved; Approved; Approved
717,2447-57-6,https://drugs.ncats.io/drug/88463U4SM5,US Previously Marketed 1981,FANSIDAR by ROCHE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018557,US Previously Marketed 1981,FANSIDAR by ROCHE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018557,Plasmodium falciparum malaria,Approved
718,127-69-5,https://drugs.ncats.io/drug/740T4C525W,US Previously Marketed 1949,Gantrisin by Hoffmann-La Roche,DeHaen 1940-1975 NMEs,US Previously Marketed 1948,GANTRISIN by ROCHE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=006525,Acute otitis media,Approved
719,144-82-1,https://drugs.ncats.io/drug/25W8454H16,US Previously Marketed 1961,THIOSULFIL SULFAMETHIZOLE by AYER5T,https://patents.google.com/patent/US20170253372A1/en,US Previously Marketed 1953,THIOSULFIL by WYETH AYERST,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=008565,Urinary tract infections,Approved
720,723-46-6,https://drugs.ncats.io/drug/JE42381TNV,US Approved Rx 2019,ANDA212231,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212231,US Previously Marketed 1961,GANTANOL by ROCHE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012715,Shigellosis; Pneumocystis jiroveci pneumonia; Urinary tract infections; Travelers’ diarrhea; Acute exacerbations of chronic bronchitis in adults; Acute otitis media,Approved; Approved; Approved; Approved; Approved; Approved
721,63-74-1,https://drugs.ncats.io/drug/21240MF57M,US Previously Marketed 1965,AVC by MYLAN SPECIALITY LP,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=006530,US Previously Marketed 1936,sulfanilamide,https://archive.org/details/newnonofficialre39coun,Vulvovaginal candidiasis,Approved
722,144-83-2,https://drugs.ncats.io/drug/Y5V2N1KE8U,US Previously Marketed 1938,M&B 693 by May & Baker,https://books.google.com/books?id=AqzmCwAAQBAJ&lpg=PA9&ots=WuZEH-OpEK&dq=sulfapyridine%20introduced%20to%20the%20US&pg=PA9#v=onepage&q=sulfapyridine%20introduced%20to%20the%20US&f=false,US Previously Marketed 1938,M&B 693 by May & Baker,https://books.google.com/books?id=AqzmCwAAQBAJ&lpg=PA9&ots=WuZEH-OpEK&dq=sulfapyridine%20introduced%20to%20the%20US&pg=PA9#v=onepage&q=sulfapyridine%20introduced%20to%20the%20US&f=false,Dermatitis herpetiformis,Approved
723,599-79-1,https://drugs.ncats.io/drug/3XC8GUZ6CB,US Approved Rx 1977,ANDA085828,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=085828,US Approved Rx 1950,NDA007073,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=007073,Rheumatoid arthritis; Ulcerative colitis,Approved; Approved
724,72-14-0,https://drugs.ncats.io/drug/Y7FKS2XWQH,US Previously Marketed 1985,TRIPLE SULFA by FOUGERA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=088463,US Previously Marketed 1940,Sulfathiazole by Winthrop,https://books.google.com/books?id=pm9KAQAAIAAJ&lpg=PA470&ots=aA7IeOI1kb&dq=cyverine%20suspended&pg=PA470#v=onepage&q=cyverine%20suspended&f=false,Vaginal infections,Approved
725,57-96-5,https://drugs.ncats.io/drug/V6OFU47K3W,US Previously Marketed 1959,ANTURANE by NOVARTIS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011556,US Previously Marketed 1959,ANTURANE by NOVARTIS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011556,Gouty arthritis,Approved
726,7134-11-4,https://drugs.ncats.io/drug/6L00O0WHZR,Clinical ,INN:sulfogaiacol [INN],https://ginas.ncats.nih.gov/ginas/app/substance/6L00O0WHZR,,,,Common cold; Asthma; Respiratory infections,Not Provided; Not Provided; Not Provided
727,7704-34-9,https://drugs.ncats.io/drug/a781d1f2,,,,,,,,
728,7664-93-9,https://drugs.ncats.io/drug/O40UQP6WCF,US Approved Rx 2023,ANDA215469,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215469,US Previously Marketed 1921,Potassium Sulphate N.F.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Bowel Cleanser,Approved
729,2551-62-4,https://drugs.ncats.io/drug/WS7LR3I1D6,US Approved Rx 2014,NDA203684,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203684,US Approved Rx 2014,NDA203684,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203684,Vesicoureteral reflux; Heart Disease; Focal liver lesions,Approved; Approved; Approved
730,38194-50-2,https://drugs.ncats.io/drug/184SNS8VUH,US Approved Rx 1991,ANDA072050,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=072050,US Previously Marketed 1978,CLINORIL by MERCK,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017911,Ankylosing spondylitis; Osteoarthritis; Rheumatoid arthritis,Approved; Approved; Approved
731,68238-36-8,https://drugs.ncats.io/drug/39N9K8S2A4,US Approved Rx 2021,ANDA213130,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213130,US Previously Marketed 1981,LYMPHAZURIN by COVIDIEN,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018310,Lymphatic vessel delineation,Approved
732,103628-46-2,https://drugs.ncats.io/drug/8R78F6L9VO,US Approved Rx 2009,ANDA079123,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=079123,US Approved Rx 1992,NDA020080,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020080,Cluster headache; Migraine without aura; Migraine with aura,Approved; Approved; Approved
733,557795-19-4,https://drugs.ncats.io/drug/V99T50803M,US Approved Rx 2023,ANDA218012,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218012,US Approved Rx 2006,NDA021968,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021968,Gastrointestinal stromal tumor; Advanced renal cell carcinoma; Pancreatic neuroendocrine tumors,Approved; Approved; Approved
734,40828-46-4,https://drugs.ncats.io/drug/988GU2F9PE,US Previously Marketed 1985,Suprol by Ortho,OB NME Appendix 1950-1993,US Previously Marketed 1985,Suprol by Ortho,OB NME Appendix 1950-1993,Intraoperative miosis,Approved
735,1339940-90-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
736,9031-11-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
737,1326244-10-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
738,89987-06-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
739,26839-75-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
740,148159-84-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
741,9005-49-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
742,65899-73-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
743,154-42-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
744,1953-02-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
745,3313-26-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
746,136310-93-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
747,183204-74-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
748,174484-41-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
749,144494-65-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
750,7440-32-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
751,51322-75-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
752,32986-56-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
753,41708-72-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
754,477600-75-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
755,1156-19-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
756,59-98-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
757,64-77-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
758,134308-13-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
759,26171-23-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
760,2398-96-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
761,124937-51-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
762,119-53-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
763,150683-30-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
764,56-40-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
765,137-58-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
766,97240-79-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
767,123948-87-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
768,56211-40-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
769,89778-26-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
770,192391-48-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
771,114899-77-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
772,123154-38-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
773,871700-17-3,https://drugs.ncats.io/drug/33E86K87QN,US Approved Rx 2013,NDA204114,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204114,US Approved Rx 2013,NDA204114,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204114,Melanoma,Approved
774,87679-37-6,https://drugs.ncats.io/drug/1T0N3G9CRC,US Approved Rx 2010,ANDA079135,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=079135,US Previously Marketed 1996,TARKA by ABBVIE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020591,Hypertension; Heart failure post myocardial infarction,Approved; Approved
775,1197-18-8,https://drugs.ncats.io/drug/6T84R30KC1,US Approved Rx 2017,ANDA206713,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206713,US Previously Marketed 1986,CYKLOKAPRON by PHARMACIA AND UPJOHN,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019280,Cyclic heavy menstrual bleeding,Approved
776,53902-12-8,https://drugs.ncats.io/drug/HVF50SMY6E,Possibly Marketed Outside US ,Japan:Tranilast,https://tripod.nih.gov/npc/#Download,,,,Bronchial asthma; Allergic rhinitis; Keloid,Approved; Approved; Approved
777,3721-26-4,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
778,180288-69-1,https://drugs.ncats.io/drug/P188ANX8CK,US Approved Rx 2019,BLA761100,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761100,US Approved Rx 1998,BLA103792,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103792,,
779,1018448-65-1,https://drugs.ncats.io/drug/SE2KH7T06F,US Approved Rx 2013,BLA125427,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125427,US Approved Rx 2013,BLA125427,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125427,Breast cancer,Approved
780,157283-68-6,https://drugs.ncats.io/drug/WJ68R08KX9,US Approved Rx 2023,NDA218010,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218010,US Previously Marketed 2001,TRAVATAN by ALCON PHARMS LTD,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021257,Open-angle glaucoma; Infertility; Labor delay,Approved; Preclinical; Preclinical
781,19794-93-5,https://drugs.ncats.io/drug/YBK48BXK30,US Approved Rx 2020,ANDA204852,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204852,US Previously Marketed 1981,DESYREL by PRAGMA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018207,Alzheimer’s disease; Major depressive disorder; Insomnia,Phase III; Approved; Phase IV
782,81846-19-7,https://drugs.ncats.io/drug/RUM6K67ESG,US Approved Rx 2009,NDA022387,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022387,US Approved Rx 2002,NDA021272,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=21272,Pulmonary arterial hypertension,Approved
783,302-79-4,https://drugs.ncats.io/drug/5688UTC01R,US Approved Rx 2019,ANDA211644,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211644,US Previously Marketed 1971,RETIN-A by VALEANT INTL,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016921,severe recalcitrant nodular acne; Acne vulgaris; Acute promyelocytic leukemia; AIDS-related Kaposi’s sarcoma,Approved; Approved; Approved; Approved
784,102-76-1,https://drugs.ncats.io/drug/XHX3C3X673,US Previously Marketed 1957,Fungacetin by Harvey,DeHaen 1940-1975 NMEs,US Previously Marketed 1957,Fungacetin by Harvey,DeHaen 1940-1975 NMEs,Major depressive disorder,Approved
785,124-94-7,https://drugs.ncats.io/drug/1ZK20VI6TY,US Previously Marketed 1975,TRIAMCINOLONE by BARR,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=084268,US Previously Marketed 1957,ARISTOCORT by ASTELLAS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011161,Perennial or seasonal allergic rhinitis; Congenital adrenal hyperplasia; Leukemias and lymphomas; Bullous dermatitis herpetiformi; Uveitis,Approved; Approved; Approved; Approved; Approved
786,918504-65-1,https://drugs.ncats.io/drug/207SMY3FQT,US Approved Rx 2011,NDA202429,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202429,US Approved Rx 2011,NDA202429,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202429,Advanced melanoma,Approved
787,1257044-40-8,https://drugs.ncats.io/drug/N54AIC43PW,US Approved Rx 2016,NDA208573,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208573,US Approved Rx 2016,NDA208573,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208573,Refractory myeloma; Acute myeloid leukemia; Chronic lymphocytic leukemia,Phase III; Phase III; Approved
788,93413-69-5,https://drugs.ncats.io/drug/GRZ5RCB1QG,US Approved Rx 2018,ANDA206250,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206250,US Previously Marketed 1993,EFFEXOR by WYETH PHARMS INC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020151,Major depressive disorder; Social anxiety disorder,Approved; Approved
789,52-53-9,https://drugs.ncats.io/drug/CJ0O37KU29,US Approved Rx 1987,ANDA070738,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=070738,US Previously Marketed 1978,Depakene by Abbott,OB NME Appendix 1950-1985,Essential hypertension; Arrhythmia; Angina,Approved; Approved; Approved
790,129497-78-5,https://drugs.ncats.io/drug/0X9PA28K43,US Approved Rx 2000,NDA021119,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021119,US Approved Rx 2000,NDA021119,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021119,Subfoveal choroidal neovascularization,Approved
791,1638194-78-1,https://drugs.ncats.io/drug/7XZ4062R17,US Approved Rx 2017,BLA761047,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761047,US Approved Rx 2017,BLA761047,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761047,,
792,5536-17-4,https://drugs.ncats.io/drug/3XQD2MEW34,US Approved Rx 2005,ANDA077133,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=077133,US Previously Marketed 1976,VIRA-A by PARKEDALE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050486,Keratoconjunctivitis; Epithelial keratitis; Herpes simplex infection; Paroxysmal supraventricular tachycardia,Approved; Approved; Phase III; Approved
793,68506-86-5,https://drugs.ncats.io/drug/GR120KRT6K,US Approved Rx 2022,ANDA214961,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214961,US Approved Rx 2009,NDA020427,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020427,Epilepsy,Approved
794,503068-34-6,https://drugs.ncats.io/drug/028LZY775B,US Approved Rx 2017,NDA209482,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209482,US Approved Rx 2013,NDA204275,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204275,Chronic obstructive pulmonary disease,Approved
795,163521-12-8,https://drugs.ncats.io/drug/S239O2OOV3,US Approved Rx 2023,ANDA208228,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208228,US Approved Rx 2011,NDA022567,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022567,Major depressive disorder,Approved
796,865-21-4,https://drugs.ncats.io/drug/5V9KLZ54CY,US Approved Rx 1987,ANDA089515,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=089515,US Previously Marketed 1961,VELBAN by LILLY,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012665,Non-Hodgkin's lymphoma; Hodgkin's lymphoma; Kaposi’s sarcoma; Carcinoma of the testis; Letterer-Siwe disease (histiocytosis X); Mycosis fungoides,Approved; Approved; Approved; Approved; Approved; Approved
797,57-22-7,https://drugs.ncats.io/drug/5J49Q6B70F,US Approved Rx 1988,ANDA071484,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=071484,US Previously Marketed 1963,ONCOVIN by LILLY,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=014103,,
798,71486-22-1,https://drugs.ncats.io/drug/Q6C979R91Y,US Approved Rx 2012,ANDA091106,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=091106,US Previously Marketed 1994,NAVELBINE by PIERRE FABRE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020388,Breast cancer; Non-small cell lung cancer,Approved; Approved
799,42971-09-5,https://drugs.ncats.io/drug/543512OBTC,Possibly Marketed Outside US ,Japan:Vinpocetine,https://tripod.nih.gov/npc/#Download,,,,Vascular dementia; Acute ischemic stroke; Epilepsy,Approved; Phase III; Phase II
800,879085-55-9,https://drugs.ncats.io/drug/25X868M3DS,US Approved Rx 2012,NDA203388,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203388,US Approved Rx 2012,NDA203388,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203388,Basal cell carcinoma,Approved
801,123-31-9,https://drugs.ncats.io/drug/XV74C1N1AE,US Approved Rx 2002,NDA021112,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021112,Possibly Marketed Outside US 1984,"NU-DERM SUNFADER  Skin Lightener with Sunscreen (SPF 15) PABA FREE by OMP, INC.",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c67b0629-5529-412d-99ee-186df4ecad5a,Melasma of the face,Approved
802,1406-18-4,https://drugs.ncats.io/drug/ec554f7b,,,,,,,,
803,50-81-7,https://drugs.ncats.io/drug/PQ6CK8PD0R,US Approved Rx 2018,NDA209381,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209381,US Previously Marketed 1947,BEROCCA PN by ROCHE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=006071,Scurvy; Vitamin C deficiency,Approved; Approved
804,12001-79-5,https://drugs.ncats.io/drug/2OYE00PC25,US Approved Rx 2023,NDA215830,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215830,US Approved Rx 2023,NDA215830,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215830,,
805,184362-10-5,https://drugs.ncats.io/drug/C3JJ5TC7LJ,,,,,,,,
806,618385-01-6,https://drugs.ncats.io/drug/ZCE93644N2,US Approved Rx 2014,NDA204886,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204886,US Approved Rx 2014,NDA204886,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204886,Peripheral arterial disease; Myocardial infarction,Approved; Approved
807,1646819-03-5,https://drugs.ncats.io/drug/2SPI046IKD,Possibly Marketed Outside US 2017,BLA125610,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=08313a24-e7ce-457a-bb3f-161bc45517ee,Possibly Marketed Outside US 2017,BLA125610,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=08313a24-e7ce-457a-bb3f-161bc45517ee,,
808,757971-58-7,https://drugs.ncats.io/drug/743QUY4VD8,US Approved Rx 2020,BLA761145,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761145,US Approved Rx 2005,BLA021859,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021859,,
809,188416-29-7,https://drugs.ncats.io/drug/USG4B1CD29,US Approved Rx 2016,ANDA206747,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206747,US Approved Rx 2002,NDA021267,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021267,Esophageal candidiasis; Fusarium spp.; Scedosporium apiospermum infection; Invasive aspergillosis,Approved; Approved; Approved; Approved
810,149647-78-9,https://drugs.ncats.io/drug/58IFB293JI,US Approved Rx 2006,NDA021991,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021991,US Approved Rx 2006,NDA021991,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021991,Cutaneous T-cell lymphoma,Approved
811,508233-74-7,https://drugs.ncats.io/drug/3O2K1S3WQV,US Approved Rx 2013,NDA204447,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204447,US Approved Rx 2013,NDA204447,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204447,Major depressive disorder,Approved
812,1535212-07-7,https://drugs.ncats.io/drug/0570F37359,US Approved Rx 2017,NDA209195,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209195,US Approved Rx 2017,NDA209195,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209195,Chronic hepatitis C,Approved
813,81-81-2,https://drugs.ncats.io/drug/5Q7ZVV76EI,US Approved Rx 2006,ANDA040616,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=040616,US Previously Marketed 1954,COUMADIN by BRISTOL MYERS SQUIBB,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=009218,Myocardial infarction; Venous thrombosis; Thromboembolic complications associated with atrial fibrillation,Approved; Approved; Approved
814,7732-18-5,https://drugs.ncats.io/drug/59a35148,,,,,,,,
815,7647-14-5,https://drugs.ncats.io/drug/451W47IQ8X,US Approved OTC ,21 CFR 349.16 ophthalmic:hypertonic agent sodium chloride,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec349-16.xml,US Previously Marketed 1921,Sodium Chloride U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,,
816,30655-48-2,https://drugs.ncats.io/drug/XY366XV8JT,Possibly Marketed Outside US 2022,M016,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27be84c1-0227-41ca-beb6-3855eff77e41,Possibly Marketed Outside US 2022,M016,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27be84c1-0227-41ca-beb6-3855eff77e41,,
817,8027-33-6,https://drugs.ncats.io/drug/884C3FA9HE,US Approved Allergenic Extract 1994,BLA103738,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f082b68-dc74-418a-9e6f-b3c285b41d44,Possibly Marketed Outside US 1957,21 CFR 334,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6601b210-3d9f-49da-a6a1-27691596b29c,,
818,121-54-0,https://drugs.ncats.io/drug/PH41D05744,US Previously Marketed 1942,Phemerol Chloride by Parke-Davis,DeHaen 1940-1975 NMEs,US Previously Marketed 1942,Phemerol Chloride by Parke-Davis,DeHaen 1940-1975 NMEs,Head and neck cancer; Methicillin-resistant Staphylococcus aureus; Skin infections; Bacterial Infections,Preclinical; Basic research; Basic research; Approved
819,11138-66-2,https://drugs.ncats.io/drug/TTV12P4NEE,US Previously Marketed ,21 CFR 310.545(a)(20) weight control xanthan gum,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec310-545.xml,Possibly Marketed Outside US 1984,Liquid Polibar Plus by E-Z-EM Canada Inc,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5b78c1b9-3013-4add-b439-663c419054b3,,
820,437-74-1,https://drugs.ncats.io/drug/8G60H12X2D,Possibly Marketed Outside US ,WHO-ATC:C04AD02,https://ginas.ncats.nih.gov/ginas/app/substance/8G60H12X2D,,,,Cerebrovascular disorders; Peripheral vascular disease,Approved; Approved
821,127-40-2,https://drugs.ncats.io/drug/X72A60C9MT,Possibly Marketed Outside US ,"Strovite One Caplets by Exeltis Usa, Inc.",https://www.drugbank.ca/drugs/DB00137,Possibly Marketed Outside US 2001,"Strovite OneCaplets by Exeltis USA, Inc.",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b9b71fa4-89c7-4f5b-8174-950649434ba5,Age-related macular degeneration; Subclinical atherosclerosis; Alzheimer’s disease,Approved; Phase III; Phase II
822,87-99-0,https://drugs.ncats.io/drug/VCQ006KQ1E,Possibly Marketed Outside US ,"L'ECLAT Blanc Toothpaste by Toaon Co., Ltd.",https://www.drugbank.ca/drugs/DB11195,Possibly Marketed Outside US 1978,60-Second Fluoride Pina Colada by Patterson Dental Supply Inc,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ad3685e0-c6f0-49dd-b638-eec7ec7be795,Acute otitis media; Osteoporosis; Dental caries; Diabetes mellitus,Approved; Preclinical; Approved; Approved
823,526-36-3,https://drugs.ncats.io/drug/WPY40FTH8K,US Approved OTC ,21 CFR 341.20(b)(10) cough/cold:nasal decongestant xylometazoline hydrochloride,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec341-20.xml,US Previously Marketed 1959,Otrivin by Ciba Geigy,OB NME Appendix 1950-1985,Rhinitis; Allergic rhinitis; Common cold,Approved; Approved; Approved
824,10257-31-5,https://drugs.ncats.io/drug/2OYE00PC25,US Approved Rx 2023,NDA215830,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215830,US Approved Rx 2023,NDA215830,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215830,,
825,146-48-5,https://drugs.ncats.io/drug/2Y49VWD90Q,US Previously Marketed ,21 CFR 310.528(a) aphrodisiac yohimbinum,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec310-528.xml,Possibly Marketed Outside US 2015,NADA140866,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=479a43d4-8b9f-4bc3-a6b8-a7418fdb4626,Erectile dysfunction,Approved
826,107753-78-6,https://drugs.ncats.io/drug/XZ629S5L50,,,,,,,Asthma,Approved
827,7481-89-2,https://drugs.ncats.io/drug/6L3XT8CB3I,US Previously Marketed 1992,HIVID by ROCHE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020199,US Previously Marketed 1992,HIVID by ROCHE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020199,HIV infection,Approved
828,151319-34-5,https://drugs.ncats.io/drug/S62U433RMH,US Approved Rx 2008,ANDA077505,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=077505,US Approved Rx 1999,NDA020859,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020859,Insomnia,Approved
829,139110-80-8,https://drugs.ncats.io/drug/L6O3XI777I,US Approved Rx 1999,NDA021036,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021036,US Approved Rx 1999,NDA021036,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021036,Influenza virus infections,Approved
830,144-68-3,https://drugs.ncats.io/drug/CV0IB81ORO,Possibly Marketed Outside US ,"Ocuvel by Adler-Stern Pharmaceuticals, LLC",https://www.drugbank.ca/drugs/DB11176,Possibly Marketed Outside US 2014,"Ocuvel by Adler-Stern Pharmaceuticals, LLC",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=888dde46-a454-41cf-9a7a-31fca36e9202,Vision disorders; Cataract; Age-related memory impairment,Approved; Phase III; Phase III
831,107452-89-1,https://drugs.ncats.io/drug/7I64C51O16,US Approved Rx 2004,NDA021060,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021060,US Approved Rx 2004,NDA021060,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021060,severe chronic pain,Approved
832,30516-87-1,https://drugs.ncats.io/drug/4B9XT59T7S,US Approved Rx 2008,ANDA077981,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=077981,US Approved Rx 1987,NDA019655,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019655,HIV-1 infection,Approved
